Suchergebnisse - "дабигатран"
-
1
Autoren:
Quelle: Качественная клиническая практика, Vol 0, Iss 4, Pp 38-49 (2023)
Schlagwörter: фармакоэкономический анализ, ишемический инсульт, апиксабан, венозные тромбоэмболические осложнения, дабигатран, прямые пероральные антикоагулянты, низкомолекулярные гепарины, 3. Good health, RS1-441, фибрилляция предсердий, Pharmacy and materia medica, ривароксабан, Medical technology, R855-855.5, тромбоэмболия лёгочной артерии, тромбоз глубоких вен, пероральные антикоагулянты
-
2
Autoren:
Quelle: Качественная клиническая практика, Vol 0, Iss 4, Pp 50-59 (2023)
-
3
Autoren: et al.
Weitere Verfasser: et al.
Quelle: Pharmacy & Pharmacology; Том 11, № 6 (2023); 461-470 ; Фармация и фармакология; Том 11, № 6 (2023); 461-470 ; 2413-2241 ; 2307-9266 ; 10.19163/2307-9266-2023-11-6
Schlagwörter: дабигатран, DOACs, consumption, rivaroxaban, apixaban, dabigatran, ПОАК, потребление, ривароксабан, апиксабан
Dateibeschreibung: application/pdf
Relation: https://www.pharmpharm.ru/jour/article/view/1398/1017; Pharmacoepidemiology // Strom B.L., Kimmel S.E., Hennessy S., editors. 50th ed. John Wiley & Sons, Ltd. – 2012. DOI:10.1002/9781119959946; Чеберда А.Е. Исследования потребления лекарственных средств // Качественная клиническая практика. – 2017. – № 1. – С. 42–45.; Петров В.И., Герасименко А.С., Горбатенко В.С., Шаталова О.В. Фармакодинамика оральных антикоагулянтов у больных с фибрилляцией предсердий в остром периоде ишемического инсульта // Фармация и фармакология. – 2020. – Т. 8, № 4. – С. 222–232. DOI:10.19163/2307-9266-2020-8-4-222-232; Hanemaaijer S., Sodihardjo F., Horikx A., Wensing M., De Smet P.A., Bouvy M.L., Teichert M. Trends in antithrombotic drug use and adherence to non-vitamin K oral anticoagulants in the Netherlands // Int J Clin Pharm. – 2015. – Vol. 37, No. 6. – P. 1128–1135. DOI:10.1007/s11096-015-0174-4; Канорский С.Г. Фибрилляция предсердий в старческом возрасте: управление рисками и особенности применения прямых пероральных антикоагулянтов // Кардиология. – 2021. – Т. 61, № 6. – С. 79–87. DOI:10.18087/cardio.2021.6.n1627; Скирденко Ю.П., Николаев Н.А. Вклад приверженности терапии антикоагулянтами в риск осложнений фибрилляции предсердий // Российский кардиологический журнал. 2019. – № 2. – С. 64–69. DOI:10.15829/1560-4071-2019-2-64-69; Консенсус экспертов по снижению риска желудочно-кишечных кровотечений у пациентов, получающих оральные антикоагулянты // Терапия. – 2021. – Т. 10, № 51. – С. 23–41. DOI:10.18565/therapy.2021.10.23-41; Вавилова Т.В., Соловьева Л.В., Бекоева А.Б., Зубкова П.Ю., Воробьева Н.А., Воробьева А.И., Мельничук Е.Ю., Хруслов М.В., Вереина Н.К., Сафин Д.Д., Галявич А.С., Sluiter M., Ендубаева Г.В., Шляхто Е.В. Лучшие практики Российской Федерации в организации антикоагулянтной терапии у больных высокого риска тромбоэмболических осложнений // Российский кардиологический журнал. – 2020. – Т. 25, № 6. – С. 3945. DOI:10.15829/1560-4071-2020-3945; Niyomsri S., Nimworapan M., Wongcharoen W., Dilokthornsakul P. Economic evaluation of direct oral anticoagulants compared to warfarin for venous thromboembolism in Thailand: a cost-utility analysis // Int J Environ Res Public Health. – 2023. – Vol. 20, No. 4. – Art. ID: 3176. DOI:10.3390/ijerph20043176; Колбин А.С., Касимова А.Р., Гиляревский С.Р. Фармакоэкономическая оценка применения апиксабана для лечения и профилактики венозных тромбоэмболий в общей популяции и популяции пациентов, страдающих онкологическими заболеваниями // Качественная клиническая практика. – 2022. – № 4. – С. 38–49. DOI:10.37489/2588-0519-2022-4-38-49; Zhao Y.J., Lin L., Zhou H.J., Tan K.T., Chew A.P., Foo C.G., Oh C.T., Lim B.P., Lim W.S. Cost-effectiveness modelling of novel oral anticoagulants incorporating real-world elderly patients with atrial fibrillation // Int J Cardiol. – 2016. – Vol. 220. – P. 794–801. DOI:10.1016/j.ijcard.2016.06.087; Lorenzoni V, Pirri S, Turchetti G. Cost-effectiveness of direct non-vitamin K oral anticoagulants versus vitamin k antagonists for the management of patients with non-valvular atrial fibrillation based on available “Real-World” Evidence: The Italian National Health System Perspective // Clin Drug Investig. –2021. – Vol. 41, No. 3. – P. 255–267. DOI:10.1007/ s40261-021-01002-z; Колбин А.С., Касимова А.Р., Гиляревский С.Р. Сравнительный фармакоэкономический анализ применения апиксабана, ривароксабана и дабигатрана для профилактики развития инсульта и эмболий в сосуды большого круга кровообращения у пациентов с неклапанной фибрилляцией предсердий // Качественная клиническая практика. – 2022. – № 4. – С. 50–59. DOI:10.37489/2588-0519-2022-4-50-59; Отделенов В.А., Мирзаев К.Б., Сычёв Д.А. Возможность применения прямых пероральных антикоагулянтов для профилактики тромбоэмболических событий у пациентов с COVID-19 // Качественная клиническая практика. – 2020. – № 4S. – С. 18–22. DOI:10.37489/2588-0519-2020-S4-18-22; Отделенов В.А., Матвеев А.В., Мирзаев К.Б., Сычев Д.А. Научное обоснование и предпосылки применения прямых пероральных антикоагулянтов для профилактики тромбоэмболических осложнений у пациентов с COVID-19 // Фарматека. – 2020. – Т. 27, № 14. –С. 10–15. DOI:10.18565/pharmateca.2020.14.10-15; Yan V.K.C., Li H.L., Wei L., Knapp M.R.J., Wong I.C.K., Chan E.W. Evolving trends in consumption of direct oral anticoagulants in 65 countries/regions from 2008 to 2019 // Drugs. – 2023. – Vol. 83, No. 4. – P. 315–340. DOI:10.1007/s40265-023-01837-0; Loo S.Y., Dell’Aniello S., Huiart L., Renoux C. Trends in the prescription of novel oral anticoagulants in UK primary care // Br J Clin Pharmacol. – 2017. – Vol. 83, No. 9. –P. 2096–2106. DOI:10.1111/bcp.13299; Elewa H., Alhaddad A., Al-Rawi S., Nounou A., Mahmoud H., Singh R. Trends in oral anticoagulant use in Qatar: a 5-year experience // J Thromb Thrombolysis. – 2017. – Vol. 43, No. 3. – P. 411–416. DOI:10.1007/s11239-017-1474-4; Lippi G., Mattiuzzi C., Cervellin G., Favaloro E.J. Direct oral anticoagulants: analysis of worldwide use and popularity using google trends // Ann Transl Med. – 2017. – Vol. 5, No. 16. – Art. ID: 322. DOI:10.21037/atm.2017.06.65; Груздева А.А., Хохлов А.Л., Ильин М.В. Оральные антикоагулянты в профилактике тромоэмболических осложнений у кардиологических пациентов: анализ применения в Российской Федерации // Качественная клиническая практика. – 2020. – № 1. – С. 69–79. DOI:10.37489/2588-0519-2020-1-69-79; Воробьева Н.А., Воробьева А.И., Шемякина Н.Я., Алексеева А.С. Пациент-ориентированный подход как основа повышения эффективности и безопасности антитромботической терапии коморбидных пациентов. Роль антикоагулянтных кабинетов // Клиническая геронтология. – 2019. – Т. 25, № 11–12. – С. 19–24. DOI:10.26347/1607-2499201911-12019-024; Улумбекова Г.Э., Калашникова А.В. Подходы к формированию концепции национальной лекарственной политики. Часть 1. Анализ рынка лекарственных препаратов в РФ. ОРГЗДРАВ: новости, мнения, обучение // Вестник ВШОУЗ. – 2018. – Т. 4. – С. 53–75. DOI:10.24411/2411-8621-2018-14003; Сычев Д.А., Абдуллаев Ш.П., Мирзаев К.Б., Рыжикова К.А., Шуев Г.Н., Гришина Е.А., Созаева Ж.А., Маммаев С.Н., Гафуров Д.М., Китаева Е.Ю., Шпрах В.В., Сулейманов С.Ш., Болиева Л.З., Созаева М.С., Жучкова С.М., Гималдинова Н.Е., Сидукова Е.Е., Асоскова А.В., Мумладзе Р.Б. Генетические детерминанты безопасности применения прямого ингибитора тромбина среди этнических групп Российской Федерации // Биомедицина. – 2019. – № 1. – С. 78–94. DOI:10.33647/2074-5982-15-1-78-94; Скрипка А.И., Когай В.В., Листратов А.И., Соколова А.А., Напалков Д.А., Фомин В.В. Персонализированный подход к назначению прямых оральных антикоагулянтов: от теории к практике // Терапевтический архив. – 2019. – Т. 91, № 7. – С. 111–120. DOI:10.26442/00403660.2019.07.000045; Мирзаев К.Б., Иващенко Д.В., Володин И.В., Гришина Е.А., Акмалова К.А., Качанова А.А., Скрипка А.И., Миннигулов Р.М., Морозова Т.Е., Батурина О.А., Леванов А.Н., Шелехова Т.В., Калинкин А.И., Напалков Д.А., Соколова А.А., Андреев Д.А., Сычев И.Н., Бочков П.О., Сычев Д.А. Новые фармакогенетические маркеры риска кровотечений на фоне применения прямых оральных антикоагулянтов // Рациональная фармакотерапия в кардиологии. – 2020. – Т. 16, № 5. – С. 670–677. DOI:10.20996/1819-6446-2020-10-05; https://www.pharmpharm.ru/jour/article/view/1398
-
4
Autoren:
Quelle: Качественная клиническая практика, Vol 0, Iss 1, Pp 69-79 (2020)
Schlagwörter: 2. Zero hunger, варфарин, апиксабан, дабигатран, 3. Good health, RS1-441, 03 medical and health sciences, Pharmacy and materia medica, 0302 clinical medicine, ривароксабан, Medical technology, персонализированный выбор антикоагулянта, R855-855.5, фармакогенетический подход
Zugangs-URL: https://www.clinvest.ru/jour/article/download/491/494
https://doaj.org/article/44c980bd16aa4ab28ad5de4a09f5d47d
https://cyberleninka.ru/article/n/oralnye-antikoagulyanty-v-profilaktike-tromoembolicheskih-oslozhneniy-u-kardiologicheskih-patsientov-analiz-primeneniya-v-rossiyskoy
https://www.clinvest.ru/jour/article/view/491
https://cyberleninka.ru/article/n/oralnye-antikoagulyanty-v-profilaktike-tromoembolicheskih-oslozhneniy-u-kardiologicheskih-patsientov-analiz-primeneniya-v-rossiyskoy/pdf
https://www.clinvest.ru/jour/article/download/491/494 -
5
Autoren: et al.
Quelle: Rational Pharmacotherapy in Cardiology; Vol 19, No 3 (2023); 290-297 ; Рациональная Фармакотерапия в Кардиологии; Vol 19, No 3 (2023); 290-297 ; 2225-3653 ; 1819-6446
Schlagwörter: дабигатран, blood concentration of anticoagulants, atrial fibrillation, apixaban, rivaroxaban, dabigatran, концентрация антикоагулянтов в крови, фибрилляция предсердий, апиксабан, ривароксабан
Dateibeschreibung: application/pdf
Relation: https://www.rpcardio.com/jour/article/view/2922/2430; Chan N, Sager PT, Lawrence J, et al. Is there a role for pharmacokinetic/ phar macodynamic-guided dosing for novel oral anticoagulants? Am Heart J. 2018;199:59-67. DOI:10.1016/j.ahj.2017.10.002.; Chan NC, Eikelboom JW, Weitz JI. Evolving Treatments for Arterial and Venous Thrombosis: Role of the Direct Oral Anticoagulants. Circ Res. 2016;118(9):14091424. DOI:10.1161/CIRCRESAHA.116.306925.; Lee JJ, Ha ACT, Dorian P, Verma M, et al. Meta-Analysis of Safety and Efficacy of Direct Oral Anticoagulants Versus Warfarin According to Time in Therapeutic Range in Atrial Fibrillation. Am J Cardiol. 2021;140:62-68. DOI:10.1016/j.amjcard.2020.10.064.; Gosselin RC, Adcock DM, Bates SM, et al. International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants. Thromb Haemost. 2018;118(3):437-450. DOI:10.1055/s-0038-1627480.; Douxfils J, Ageno W, Samama CM, et al. Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. J Thromb Haemost. 2018;16(02):209-219. DOI:10.1111/jth.13912.; Toorop MMA, Lijfering WM, Scheres LJJ. The relationship between DOAC levels and clinical outcomes: The measures tell the tale. J Thromb Haemost. 2020;18(12):3163-3168. DOI:10.1111/jth.15104.; Douxfils J, Mullier F, Dogné JM. Dose tailoring of dabigatran etexilate: obvious or excessive? Expert Opin Drug Saf. 2015;14(8):1283-1289. DOI:10.1517/14740338.2015.1049995.; Kato ET, Giugliano RP, Ruff CT, et al. Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. J Am Heart Assoc. 2016;5(05):e003432. DOI:10.1161/JAHA.116.003432.; Buckley LF, Rybak E, Aldemerdash A, et al. Direct oral anticoagulants in patients with atrial fibrillation and renal impairment, extremes in weight, or advanced age. Clin Cardiol. 2017;40(01):46-52. DOI:10.1002/clc.22591.; Chan KE, Giugliano RP, Patel MR, et al. Nonvitamin K anticoagulant agents in patients with advanced chronic kidney disease or on dialysis with AF. J Am Coll Cardiol. 2016;67(24):2888-2899. DOI:10.1016/j.jacc.2016.02.082.; Levy JH, Ageno W, Chan NC, et al.; Subcommittee on Control of Anticoagulation. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost. 2016;14(03):623-627. DOI:10.1111/jth.13227.; Lindhoff-Last E. Direct oral anticoagulants (DOAC) — Management of emergency situations. Hamostaseologie. 2017;37(4):257-266. DOI:10.5482/HAMO-16-11-0043.; Gendron N, Gay J, Lemoine M, et al. Usefulness of initial plasma dabigatran concentration to predict rebound after reversal. Haematologica. 2018; 103(05):e226-e229. DOI:10.3324/haematol.2017.183400.; Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):13301393. DOI:10.1093/eurheartj/ehy136.; Tripodi A. To measure or not to measure direct oral anticoagulants before surgery or invasive procedures: reply. J Thromb Haemost. 2016;14(12):25592561. DOI:10.1111/jth.13513.; Tripodi A. To measure or not to measure direct oral anticoagulants before surgery or invasive procedures. J Thromb Haemost. 2016;14(7):1325-1327. DOI:10.1111/jth.13344.; Tripodi A, Marongiu F, Moia M, et al. The vexed question of whether or not to measure levels of direct oral anticoagulants before surgery or invasive procedures. Intern Emerg Med. 2018;13(7):1029-1036. DOI:10.1007/s11739-018-1854-6.; Albaladejo P, Bonhomme F, Blais N, et al. Management of direct oral anticoagulants in patients undergoing elective surgeries and invasive procedures: Updated guidelines from the French Working Group on Perioperative Hemostasis (GIHP) — September 2015. Anaesth Crit Care Pain Med. 2017;36(1):73-76. DOI:10.1016/j.accpm.2016.09.002.; Rimsans J, Douxfils J, Smythe MA, Gosselin RC. Overview and Practical Application of Coagulation Assays in Managing Anticoagulation with Direct Oral Anticoagulants (DOACs). Curr Pharmacol Rep. 2020;6:241-259. DOI:10.1007/s40495-020-00232-7.; Douketis JD, Spyropoulos AC, Duncan J, et al. Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant. JAMA Intern Med. 2019;179(11):1469-1478. DOI:10.1001/jamainternmed.2019.2431.; Shaw JR, Li N, Vanassche T, Coppens M, et al. Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure. Blood Adv. 2020;4(15):3520-3527. DOI:10.1182/bloodadvances.2020002335.; Martin K, Beyer-Westendorf J, Davidson BL, et al. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost. 2016;14(6):1308-1313. DOI:10.1111/jth.13323.; Moll S, Crona DJ, Martin K. Direct oral anticoagulants in extremely obese patients: OK to use? Res Pract Thromb Haemost. 2018;3(2):152-155. DOI:10.1002/rth2.12178.; Jamieson MJ, Byon W, Dettloff RW, et al. Apixaban Use in Obese Patients: A Review of the Pharmacokinetic, Interventional, and Observational Study Data. Am J Cardiovasc Drugs. 2022;22(6):615-631. DOI:10.1007/s40256-022-00524-x.; Testa S, Legnani C, Antonucci E, et al. Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants. J Thromb Haemost. 2019;17(7):1064-1072. DOI:10.1111/jth.14457.; Testa S, Paoletti O, Legnani C, et al. Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants. J Thromb Haemost. 2018;16(5):842-848. DOI:10.1111/jth.14001.; Salmonson T, Dogné JM, Janssen H, et al. Non-vitamin-K oral anticoagulants and laboratory testing: now and in the future: Views from a workshop at the European Medicines Agency (EMA). Eur Heart J Cardiovasc Pharmacother. 2017;3:(1):42-47. DOI:10.1093/ehjcvp/pvw032.; Meinel TR, Wilson D, Gensicke H, et al.; DOAC-IVT Writing Group for the International DOAC-IVT, TRISP, and CRCS-K-NIH Collaboration. Intravenous Thrombolysis in Patients With Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants. JAMA Neurol. 2023;80(3):233-243. DOI:10.1001/jamaneurol.2022.4782. Erratum in: JAMA Neurol. 2023;80(4):422.; Willmann S, Thelen K, Kubitza D, et al. Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling: an EINSTEIN-Jr phase I study. Thromb J. 2018;16:32. DOI:10.1186/s12959-018-0185-1.; Rahman M, George C, Monagle P. Hot topics in coagulation testing: Important considerations for testing children for bleeding/thrombotic disorders. Int J Lab Hematol. 2020;42(1):68-74. DOI:10.1111/ijlh.13198.; Sarode R. Direct oral anticoagulant monitoring: what laboratory tests are available to guide us? Hematology Am Soc Hematol Educ Program. 2019;2019(1):194–197. DOI:10.1182/hematology.2019000027.; Douxfils J, Adcock DM, Bates SM, Favaloro EJ, et al. 2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. Thromb Haemost. 2021;121(8):1008-1020. DOI:10.1055/a-1450-8178.; Tarn D, Shih K, Tseng C, et al. Reasons for Nonadherence to the Direct Oral Anticoagulant Apixaban: A Cross-Sectional Survey of Atrial Fibrillation Patients. JACC Adv. 2023;2(1):100175. DOI:10.1016/j.jacadv.2022.100175.; Samoš M, Bolek T, Stančiaková L, et al. Tailored Direct Oral Anticoagulation in Patients with Atrial Fibrillation: The Future of Oral Anticoagulation? J Clin Med. 2022;11(21):6369. DOI:10.3390/jcm11216369.; Reilly PA, Lehr T, Haertter S, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol. 2014;63(4):321-328. DOI:10.1016/j.jacc.2013.07.104.; Sakaguchi T, Osanai H, Murase Y, et al. Monitoring of anti-Xa activity and factors related to bleeding events: A study in Japanese patients with nonvalvular atrial fibrillation receiving rivaroxaban. J Cardiol. 2017;70(3):244-249. DOI:10.1016/j.jjcc.2016.11.013.; Gao H, Li Y, Sun H, et al. Trough Concentration Deficiency of Rivaroxaban in Patients With Nonvalvular Atrial Fibrillation Leading to Thromboembolism Events. J Cardiovasc Pharmacol. 2022;80(6):869-876. DOI:10.1097/FJC.0000000000001360.; Sin CF, Wong KP, Wong HM, et al. Plasma Rivaroxaban Level in Patients With Early Stages of Chronic Kidney Disease-Relationships With Renal Function and Clinical Events. Front Pharmacol. 2022;13:888660. DOI:10.3389/fphar.2022.888660.; Škorňová I, Samoš M, Bolek T, et al. Direct Oral Anticoagulants Plasma Levels in Patients with Atrial Fibrillation at the Time of Bleeding: A Pilot Prospective Study. J Cardiovasc Pharmacol. 2021;78(1):e122-e127. DOI:10.1097/FJC.0000000000001038.; Nosáľ V, Petrovičová A, Škorňová I, et al. Plasma levels of direct oral anticoagu- lants in atrial fibrillation patients at the time of embolic stroke: a pilot prospective multicenter study. Eur J Clin Pharmacol. 2022;78(4):557-564. DOI:10.1007/s00228-022-03280-8.; Favaloro EJ, Pasalic L, Curnow J, Lippi G. Laboratory Monitoring or Measure - ment of Direct Oral Anticoagulants (DOACs): Advantages, Limitations and Future Challenges. Curr Drug Metab. 2017;18(7):598-608. DOI:10.2174/1389200218666170417124035.; Yates SG, Smith S, Tharpe W, et al. Can an anti-Xa assay for low-molecular-weight heparin be used to assess the presence of rivaroxaban? Transfus Apher Sci. 2016;55(2):212-215. DOI:10.1016/j.transci.2016.06.005.; Sabor L, Raphaël M, Dogné JM, et al. Heparin-calibrated chromogenic anti-Xa assays are not suitable to assess the presence of significant direct factor Xa inhibitors levels. Thromb Res. 2017;156:36-38. DOI:10.1016/j.thromres.2017.05.024.; Margetić S, Ćelap I, Delić Brkljačić D, et al. Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations. Biochem Med (Zagreb). 2020;30(1):010702. doi:10.11613/BM.2020.010702.; Sairaku A, Nakano Y, Onohara Y, et al. Residual anticoagulation activity in atrial fibrillation patients with temporary interrupted direct oral anticoagulants: Comparisons across 4 drugs. Thromb Res. 2019;183:119-123. DOI:10.1016/j.thromres.2019.10.006.; Artang R, Dias JD, Walsh M, et al. Measurement of Anticoagulation in Patients on Dabigatran, Rivaroxaban, and Apixaban Therapy by Novel Automated Thrombelastography. TH Open. 2021;5(4):e570-e576. DOI:10.1055/a-1692-1415.; Cayla G, Cuisset T, Silvain J, et al. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. Lancet. 2016;388(10055):2015-2022. DOI:10.1016/S01406736(16)31323-X.; https://www.rpcardio.com/jour/article/view/2922
-
6
Autoren: et al.
Quelle: Rational Pharmacotherapy in Cardiology; Vol 18, No 6 (2022); 727-733 ; Рациональная Фармакотерапия в Кардиологии; Vol 18, No 6 (2022); 727-733 ; 2225-3653 ; 1819-6446
Schlagwörter: кардиомиопатия, warfarin, anticoagulants, left ventricular thrombosis, direct oral anticoagulants, apixaban, rivaroxaban, dabigatran, myocardial infarction, cardiomyopathy, варфарин, антикоагулянты, тромбоз левого желудочка, прямые оральные антикоагулянты, апиксабан, ривароксабан, дабигатран, инфаркт миокарда
Dateibeschreibung: application/pdf
Relation: https://www.rpcardio.com/jour/article/view/2862/2388; Ibanez B, James S, Agewall S, et al. ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-77. DOI:10.1093/eurheartj/ehx393.; Кропачева Е.С. Внутрисердечный тромбоз: частота, факторы риска и место пероральных антикоагулянтов в лечении. Атеротромбоз. 2020;(1):134-52. DOI:10.21518/2307-1109-2020-1-134-152.; Habash F, Vallurupalli S. Challenges in management of left ventricular thrombus. Ther Adv Cardiovasc Dis. 2017;11(8):203-13. DOI:10.1177/1753944717711139.; Robinson AA, Jain A, Gentry M, McNamara RL. Left ventricular thrombi after STEMI in the primary PCI era: A systematic review and meta-analysis. Int J Cardiol. 2016;221:554-9. DOI:10.1016/j.ijcard.2016.07.069.; Pöss J, Desch S, Eitel C, et al. Left Ventricular Thrombus Formation After ST-Segment-Elevation Myocardial Infarction: Insights From a Cardiac Magnetic Resonance Multicenter Study. Circ Cardiovasc Imaging. 2015;8(10):e003417. DOI:10.1161/CIRCIMAGING.115.003417.; Delewi R, Zijlstra F, Piek JJ. Left ventricular thrombus formation after acute myocardial infarction. Heart. 2012;98(23):1743-9. DOI:10.1136/heartjnl-2012-301962.; Roifman I, Connelly KA, Wright GA, Wijeysundera HC. Echocardiography vs. Cardiac Magnetic Resonance Imaging for the Diagnosis of Left Ventricular Thrombus: A Systematic Review. Can J Cardiol. 2015;31(6):785-91. DOI:10.1016/j.cjca.2015.01.011.; Weinsaft JW, Kim J, Medicherla CB, et al. A Novel Imaging Algorithm for Post Myocardial Infarction Left Ventricular Thrombus – Regional LV Function on Echocardiography as a Gatekeeper for Thrombus Evaluation by Delayed Enhancement Cardiac Magnetic Resonance. JACC Cardiovasc Imaging. 2016;9(5):505-15. DOI:10.1016/j.jcmg.2015.06.017.; Dinesh Kumar US, Shetty SP, Sujay KR, Wali M. Left ventricular mass: A tumor or a thrombus diagnostic dilemma. Ann Card Anaesth. 2016;19(4):728-32. DOI:10.4103/0971-9784.191551.; Lemaître AI, Picard F, Maurin V et al. Clinical profile and midterm prognosis of left ventricular thrombus in heart failure. ESC Heart Fail. 2021;8(2):1333-41. DOI:10.1002/ehf2.13211.; Hamada M. Left Ventricular Thrombus in Hypertrophic Cardiomyopathy. Intern Med Tokyo Jpn. 2019;58(4):465-7. DOI:10.2169/internalmedicine.1646-18.; Becker RC, Owens AP, Sadayappan S. Tissue-Level Inflammation and Ventricular Remodeling in Hypertrophic Cardiomyopathy. J Thromb Thrombolysis. 2020;49(2):177-83. DOI:10.1007/s11239-019-02026-1.; Herath HMMTB, Pahalagamage SP, Lindsay LC, et al. Takotsubo cardiomyopathy complicated with apical thrombus formation on first day of the illness: a case report and literature review. BMC Cardiovasc Disord. 2017;17(1):176. DOI:10.1186/s12872-017-0616-0.; Ding KJ, Cammann VL, Szawan KA, et al. Intraventricular Thrombus Formation and Embolism in Takotsubo Syndrome: Insights From the International Takotsubo Registry. Arterioscler Thromb Vasc Biol. 2020;40(1):279-87. DOI:10.1161/ATVBAHA.119.313491.; Шилова А.С., Шмоткина А.О., Яфарова А.А., Гиляров М.Ю. Синдром такоцубо: современные представления о патогенезе, распространенности и прогнозе. Рациональная Фармакотерапия В Кардиологии. 2018;14(4):598-604. DOI:10.20996/1819-6446-201814-4-598-604.; Chimenti C, Lavalle C, Magnocavallo M, et al. A proposed strategy for anticoagulation therapy in noncompaction cardiomyopathy. ESC Heart Fail. 2021;9(1):241-50. DOI:10.1002/ehf2.13694.; Pitta S, Thatai D, Afonso L. Thromboembolic complications of left ventricular noncompaction: case report and brief review of the literature. J Clin Ultrasound JCU. 2007;35(8):465-8. DOI:10.1002/jcu.20349.; Bakalli A, Georgievska-Ismail L, Koçinaj D, et al. Left ventricular and left atrial thrombi in sinus rhythm patients with dilated ischemic cardiomyopathy. Med Arch Sarajevo Bosnia Herzeg. 2012;66(3):155-8. DOI:10.5455/medarh.2012.66.155-158.; Chan NC, Weitz JI. COVID-19 coagulopathy, thrombosis, and bleeding. Blood. 2020;136(4):381-3. DOI:10.1182/blood.2020007335.; Giustino G, Pinney SP, Lala A, et al. Coronavirus and Cardiovascular Disease, Myocardial Injury, and Arrhythmia. J Am Coll Cardiol. 2020;76(17):2011-23. DOI:10.1016/j.jacc.2020.08.059.; Lala A, Johnson KW, Januzzi JL, et al. Prevalence and Impact of Myocardial Injury in Patients Hospitalized With COVID-19 Infection. J Am Coll Cardiol. 2020;76(5):533-46. DOI:10.1016/j.jacc.2020.06.007.; Nishiga M, Wang DW, Han Y, et al. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nat Rev Cardiol. 2020;17(9):543-58. DOI:10.1038/s41569-020-0413-9.; Diaz-Arocutipa C, Torres-Valencia J, Saucedo-Chinchay J, Cuevas C. ST-segment elevation in patients with COVID-19: a systematic review. J Thromb Thrombolysis. 2021;52(3):738-45. DOI:10.1007/s11239-021-02411-9.; Azevedo RB, Botelho BG, Hollanda JVG de, et al. Covid-19 and the cardiovascular system: a comprehensive review. J Hum Hypertens. 2021;35(1):4-11. DOI:10.1038/s41371-020-0387-4.; Fenton M, Siddavaram S, Sugihara C, Husain S. Lessons of the month 3: ST-elevation myocardial infarction and left ventricular thrombus formation: an arterial thrombotic complication of severe COVID-19 infection. Clin Med Lond Engl. 2020;20(4):437-9. DOI:10.7861/clinmed.2020-0266.; Materna O, Koubský K, Pádr R, Janoušek J. Major left ventricular thrombi in an adolescent with COVID19-associated inflammatory syndrome. Eur Heart J. 2021;42(33):3207. DOI:10.1093/eurheartj/ehab165.; O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61(4):e78-140. DOI:10.1016/j.jacc.2012.11.019.; Guyatt GH, Akl EA, Crowther M, et al. American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):7S-47S. DOI:10.1378/chest.1412S3.; Abdelnabi M, Saleh Y, Fareed A, et al. Comparative Study of Oral Anticoagulation in Left Ventricular Thrombi (No-LVT Trial). J Am Coll Cardiol. 2021;77(12):1590-2. DOI:10.1016/j.jacc.2021.01.049.; Alcalai R, Butnaru A, Moravsky G, et al. Apixaban versus Warfarin in Patients with Left Ventricular Thrombus, A Prospective Multicenter Randomized Clinical Trial. Eur Heart J Cardiovasc Pharmacother. 2022;8(7):660-7. DOI:10.1093/ehjcvp/pvab057.; Isa W Y W, Hwong N, Mohamed Yusof AK, et al. Apixaban versus Warfarin in Patients with Left Ventricular Thrombus: A Pilot Prospective Randomized Outcome Blinded Study Investigating Size Reduction or Resolution of Left Ventricular Thrombus. J Clin Prev Cardiol. 2020;9(4):150-4. DOI:10.4103/JCPC.JCPC_41_20.; Bass ME, Kiser TH, Page RL, et al. Comparative effectiveness of direct oral anticoagulants and warfarin for the treatment of left ventricular thrombus. J Thromb Thrombolysis. 2021;52(2):517-22. DOI:10.1007/s11239-020-02371-6.; Cochran JM, Jia X, Kaczmarek J, et al. Direct Oral Anticoagulants in the Treatment of Left Ventricular Thrombus: A Retrospective, Multicenter Study and Meta-Analysis of Existing Data. J Cardiovasc Pharmacol Ther. 2021;26(2):173-8. DOI:10.1177/1074248420967644.; Daher J, Da Costa A, Hilaire C, et al. Management of Left Ventricular Thrombi with Direct Oral Anticoagulants: Retrospective Comparative Study with Vitamin K Antagonists. Clin Drug Investig. 2020;40(4):343- 53. DOI:10.1007/s40261-020-00898-3.; Durrer-Ariyakuddy K, Moccetti F, Stämpfli S. Direct oral anticoagulants versus vitamin K antagonists for treatment of left ventricular thrombus – insights from multicenter registry. Cardiovasc Med. 2019;22:P27. DOI:10.4414/cvm.2019.02052.; Gama F, Freitas P, Trabulo M, et al. Direct oral anticoagulants are an effective therapy for left ventricular thrombus formation. Eur Heart J. 2019;40(Suppl_1):ehz747.0118. DOI:10.1093/eurheartj/ehz747.0118.; Guddeti RR, Anwar M, Walters RW, et al. Treatment of Left Ventricular Thrombus With Direct Oral Anticoagulants: A Retrospective Observational Study. Am J Med. 2020;133(12):1488-91. DOI:10.1016/j.amjmed.2020.05.025.; Iqbal H, Straw S, Craven TP, et al. Direct oral anticoagulants compared to vitamin K antagonist for the management of left ventricular thrombus. ESC Heart Fail. 2020;7(5):2032-41. DOI:10.1002/ehf2.12718.; Jaidka A, Zhu T, Lavi S, Johri A. Treatment of left ventricular thrombus using warfarin versus direct oral anticoagulants following anterior myocardial infarction Can J Cardiol. 2018;34(10):S143. DOI:10.1016/j.cjca.2018.07.194.; Willeford A, Zhu W, Stevens C, Thomas IC. Direct Oral Anticoagulants Versus Warfarin in the Treatment of Left Ventricular Thrombus. Ann Pharmacother. 2021;55(7):839-45. DOI:10.1177/1060028020975111.; Xu Z, Li X, Li X, et al. Direct oral anticoagulants versus vitamin K antagonists for patients with left ventricular thrombus. Ann Palliat Med. 2021;10(9):9427-34. DOI:10.21037/apm-21-1683.; Yunis A, Seese L, Stearns B, et al. Direct oral anticoagulants are effective therapy in treating left ventricular thrombi. J Am Coll Cardiol. 2020;75(11):948. DOI:10.1016/S0735-1097(20)31575-8.; Jones DA, Wright P, Alizadeh MA, et al. The use of novel oral anticoagulants compared to vitamin K antagonists (warfarin) in patients with left ventricular thrombus after acute myocardial infarction. Eur Heart J Cardiovasc Pharmacother. 2021;7(5):398-404. DOI:10.1093/ehjcvp/pvaa096.; Ali Z, Isom N, Dalia T, et al. Direct oral anticoagulant use in left ventricular thrombus. Thromb J. 2020;18:29. DOI:10.1186/s12959-020-00242-x.; Saleh Y, Al-Abcha A, Abdelkarim O, et al. Meta-Analysis Investigating the Role of Direct Oral Anticoagulants Versus Vitamin K Antagonists in the Treatment of Left Ventricular Thrombi. Am J Cardiol. 2021;150:126- 8. DOI:10.1016/j.amjcard.2021.03.032.; Saleiro C, Lopes J, De Campos D, et al. Left Ventricular Thrombus Therapy With Direct Oral Anticoagulants Versus Vitamin K Antagonists: A Systematic Review and Meta-Analysis. J Cardiovasc Pharmacol Ther. 2021;26(3):233-43. DOI:10.1177/1074248420977567.; Li S, Deng Y, Tong Y, et al. Assessment of non-vitamin K antagonist oral anticoagulants for the management of left ventricular thrombus. Clin Cardiol. 2021;44(6):754-60. DOI:10.1002/clc.23553.; Michael F, Natt N, Shurrab M. Direct Oral Anticoagulants vs Vitamin K Antagonists in Left Ventricular Thrombi: A Systematic Review and Meta-analysis. CJC Open. 2021;3(9):1169-81. DOI:10.1016/j.cjco.2021.04.007.; Trongtorsak A, Thangjui S, Kewcharoen J, et al. Direct oral anticoagulants vs. vitamin K antagonists for left ventricular thrombus: a systematic review and meta-analysis. Acta Cardiol. 2021;76(9):933-42. DOI:10.1080/00015385.2020.1858538.; Kajy M, Shokr M, Ramappa P. Use of Direct Oral Anticoagulants in the Treatment of Left Ventricular Thrombus: Systematic Review of Current Literature. Am J Ther. 2020;27(6):e584-90. DOI:10.1097/MJT.0000000000000937.; Tomasoni D, Sciatti E, Bonelli A, et al. Direct Oral Anticoagulants for the Treatment of Left Ventricular Thrombus-A New Indication? A Meta-summary of Case Reports. J Cardiovasc Pharmacol. 2020;75(6):530-4. DOI:10.1097/FJC.0000000000000826.; Abdelaziz HK, Megaly M, Debski M, et al. Meta-Analysis Comparing Direct Oral Anticoagulants to Vitamin K Antagonists for The Management of Left Ventricular Thrombus. Expert Rev Cardiovasc Ther. 2021;19(5):427-32. DOI:10.1080/14779072.2021.1915134.; Chen R, Zhou J, Liu C, et al. Direct oral anticoagulants versus vitamin K antagonists for patients with left ventricular thrombus: a systematic review and meta-analysis. Pol Arch Intern Med. 2021;131(5):429- 38. DOI:10.20452/pamw.15923.; Kido K, Ghaffar YA, Lee JC, et al. Meta-analysis comparing direct oral anticoagulants versus vitamin K antagonists in patients with left ventricular thrombus. PloS One. 2021;16(6):e0252549. DOI:10.1371/journal.pone.0252549.; Robinson AA, Trankle CR, Eubanks G, et al. Off-label Use of Direct Oral Anticoagulants Compared With Warfarin for Left Ventricular Thrombi. JAMA Cardiol. 2020;5(6):685-92. DOI:10.1001/jamacardio.2020.0652.; Lim CW, Mamat RM, Hishammudin IA, et al. Left Ventricular Thrombus: Patient Characteristics and Treatment from a Single Tertiary Centre’s Experience. Int J Cardiol. 2019;297:20-1. DOI:10.1016/j.ijcard.2019.11.056.; Degheim G, Berry A, Zughaib M. Off label use of direct oral anticoagulants for left ventricular thrombus. Is it appropriate? Am J Cardiovasc Dis. 2017;7(5):98-101.; Moey MYY, Tomdio AN, Achike O, Kabirdas D. Large Left Ventricular Thrombus as a Cause of Recurrent Cardioembolic Stroke While on Dabigatran. CASE Cardiovasc Imaging Case Rep. 2018;2(5):222-4. DOI:10.1016/j.case.2018.04.008.; Kaya A, Hayıroğlu Mİ, Keskin M, et al. Resolution of left ventricular thrombus with apixaban in a patient with hypertrophic cardiomyopathy. Turk Kardiyol Dernegi Arsivi Turk Kardiyol Derneginin Yayin Organidir. 2016;44(4):335-7. DOI:10.5543/tkda.2015.68054.; Kaku B. Intra-cardiac thrombus resolution after anti-coagulation therapy with dabigatran in a patient with mid-ventricular obstructive hypertrophic cardiomyopathy: a case report. J Med Case Reports. 2013;7:238. DOI:10.1186/1752-1947-7-238.; Elikowski W, Małek-Elikowska M, Fertała N, et al. Fast apixaban-related resolution of left ventricular thrombi in a patient with dilated cardiomyopathy. Pol Merkur Lek Organ Pol Tow Lek. 2018;44(259): 19-22.; Sun H, Zhao Q, Wang Y, et al. Daily 10 mg rivaroxaban as a therapy for ventricular thrombus related to left ventricular non-compaction cardiomyopathy. Medicine (Baltimore). 2018;97(4):e9670. DOI:10.1097/MD.0000000000009670.; Bahmaid RA, Ammar S, Al-Subaie S, et al. Efficacy of direct oral anticoagulants on the resolution of left ventricular thrombus—A case series and literature review. JRSM Cardiovasc Dis. 2019;8: 2048004019839548. DOI:10.1177/2048004019839548.; Shokr M, Ahmed A, Abubakar H, et al. Use of direct oral anticoagulants in the treatment of left ventricular thrombi: A tertiary center experience and review of the literature. Clin Case Rep. 2018;7(1):135-42. DOI:10.1002/ccr3.1917.; Smetana KS, Dunne J, Parrott K, et al. Oral factor Xa inhibitors for the treatment of left ventricular thrombus: a case series. J Thromb Thrombolysis. 2017;44(4):519-24. DOI:10.1007/s11239-017-1560-7.; Verma B, Singh A, Kumar M. Use of dabigatran for treatment of left ventricular thrombus: A tertiary care center experience. J Fam Med Prim Care. 2019;8(8):2656-60. DOI:10.4103/jfmpc.jfmpc_459_19.; https://www.rpcardio.com/jour/article/view/2862
-
7
Autoren: et al.
Quelle: Aterotromboz = Atherothrombosis; Том 13, № 1 (2023); 46-57 ; Атеротромбоз; Том 13, № 1 (2023); 46-57 ; 2658-5952 ; 2307-1109 ; 10.21518/2307-1109-2023-1
Schlagwörter: высокий риск кровотечений, anticoagulant withdrawal, coagulation tests, anti-Xa activity, diluted thrombin time, apixaban, rivaroxaban, dabigatran, chronic kidney disease, high bleeding risk, отмена антикоагулянта, коагуляционные тесты, анти-Хаактивность, разведенное тромбиновое время, апиксабан, ривароксабан, дабигатран, хроническая болезнь почек
Dateibeschreibung: application/pdf
Relation: https://www.aterotromboz.ru/jour/article/view/301/306; Панченко Е.П., Комаров А.Л., Кропачева Е.С., Добровольский А.Б. Протокол ведения пациентов, нуждающихся в длительном приеме антитромботической терапии, при инвазивных вмешательствах. Кардиологический вестник. 2020;(2):63–77. https://doi.org/10.36396/MS.2020.65.42.009.; Steffel J., Verhamme P., Potpara T.S., Albaladejo P., Antz M., Desteghe L. et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330–1393. https://doi.org/10.1093/eurheartj/ehy136.; Hindricks G., Potpara T., Dagres N., Arbelo E., Bax J.J., Blomström-Lundqvist C. et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373–498. https://doi.org/10.1093/eurheartj/ehaa612.; Douketis J.D., Healey J.S., Brueckmann M., Eikelboom J.W., Ezekowitz M.D., Fraessdorf M. et al. Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial. Thromb Haemost. 2015;113(3):625–632. https://doi.org/10.1160/TH14-04-0305.; Beyer-Westendorf J., Gelbricht V., Förster K., Ebertz F., Köhler C., Werth S. et al. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. Eur Heart J. 2014;35(28):1888–1896. https://doi.org/10.1093/eurheartj/eht557.; Nazha B., Pandya B., Cohen J., Zhang M., Lopes R.D., Garcia D.A. et al. Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation. Circulation. 2018;138(14):1402–1411. https://doi.org/10.1161/CIRCULATIONAHA.117.031457.; Shaw J.R., Li N., Vanassche T., Coppens M., Spyropoulos A.C., Syed S. et al. Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure. Blood Adv. 2020;4(15):3520–3527. https://doi.org/10.1182/bloodadvances.2020002335.; Piccolo R., Pilgrim T., Franzone A., Valgimigli M., Haynes A., Asami M. et al. Frequency, Timing, and Impact of Access-Site and Non-Access-Site Bleeding on Mortality Among Patients Undergoing Transcatheter Aortic Valve Replacement. JACC Cardiovasc Interv. 2017;10(14):1436–1446. https://doi.org/10.1016/j.jcin.2017.04.034.; Dangas G.D., Mehran R. Bleeding After Aortic Valve Replacement Matters: Important Mortality Risk. JACC Cardiovasc Interv. 2017;10(14):1447–1448. https://doi.org/10.1016/j.jcin.2017.06.005.; Wang J., Yu W., Jin Q., Li Y., Liu N., Hou X., Yu Y. Risk Factors for Post-TAVI Bleeding According to the VARC-2 Bleeding Definition and Effect of the Bleeding on Short-Term Mortality: A Meta-analysis. Can J Cardiol. 2017;33(4):525–534. https://doi.org/10.1016/j.cjca.2016.12.001.; Godier A., Dincq A.S., Martin A.C., Radu A., Leblanc I., Antona M. et al. Predictors of pre-procedural concentrations of direct oral anticoagulants: a prospective multicentre study. Eur Heart J. 2017;38(31):2431–2439. https://doi.org/10.1093/eurheartj/ehx403.; Fox V., Kleikamp A., Dittrich M., Zittermann A., Flieder T., Knabbe C. et al. Direct oral anticoagulants and cardiac surgery: A descriptive study of preoperative management and postoperative outcomes. J Thorac Cardiovasc Surg. 2021;161(5):1864–1874.e2. https://doi.org/10.1016/j.jtcvs.2019.11.119.; Reilly P.A., Lehr T., Haertter S., Connolly S.J., Yusuf S., Eikelboom J.W. et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol. 2014;63(4):321–328. https://doi.org/10.1016/j.jacc.2013.07.104.; Cirincione B., Kowalski K., Nielsen J., Roy A., Thanneer N., Byon W. et al. Population Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation. CPT Pharmacometrics Syst Pharmacol. 2018;7(11):728–738. https://doi.org/10.1002/psp4.12347.; Schellings M.W., Boonen K., Schmitz E.M., Jonkers F., van den Heuvel D.J., Besselaar A. et al. Determination of dabigatran and rivaroxaban by ultra-performance liquid chromatography-tandem mass spectrometry and coagulation assays after major orthopaedic surgery. Thromb Res. 2016;139:128–134. https://doi.org/10.1016/j.thromres.2016.01.012.; Титаева Е.В., Добровольский А.Б. Хромогенный антиХа-тест: соотношение между единицами активности гепарина и концентрацией апиксабана и ривароксабана. Атеротромбоз. 2020;(2):96–104. https://doi.org/10.21518/2307-1109-2020-2-96-104.; Spyropoulos A.C., Brohi K., Caprini J., Samama C.M., Siegal D., Tafur A. et al. Scientific and Standardization Committee Communication: Guidance document on the periprocedural management of patients on chronic oral anticoagulant therapy: Recommendations for standardized reporting of procedural/surgical bleed risk and patient-specific thromboembolic risk. J Thromb Haemost. 2019;17(11):1966–1972. https://doi.org/10.1111/jth.14598.; Godier A., Fontana P., Motte S., Steib A., Bonhomme F., Schlumberger S. et al. Management of antiplatelet therapy in patients undergoing elective invasive procedures. Proposals from the French Working Group on perioperative haemostasis (GIHP) and the French Study Group on thrombosis and haemostasis (GFHT). In collaboration with the French Society for Anaesthesia and Intensive Care Medicine (SFAR). Anaesth Crit Care Pain Med. 2018;37(4):379–389. https://doi.org/10.1016/j.accpm.2017.12.012.; Erdoes G., Wouters P.F., Alston R.P., Schreiber J.U., Bettex D., Antoniou T. et al. European Association of Cardiothoracic Anesthesiology and Intensive Care (EACTAIC) Fellowship Curriculum: Second Edition. J Cardiothorac Vasc Anesth. 2022;36(9):3483–3500. https://doi.org/10.1053/j.jvca.2022.05.022.; https://www.aterotromboz.ru/jour/article/view/301
-
8
Autoren: et al.
Quelle: Aterotromboz = Atherothrombosis; Том 12, № 2 (2022); 103-112 ; Атеротромбоз; Том 12, № 2 (2022); 103-112 ; 2658-5952 ; 2307-1109 ; 10.21518/2307-1109-2022-2
Schlagwörter: дабигатран, atrial fibrillation (AF), left atrial thrombosis, direct oral anticoagulants (DOACs), dabigatran, фибрилляция предсердий, тромбоз левого предсердия, прямые пероральные антикоагулянты
Dateibeschreibung: application/pdf
Relation: https://www.aterotromboz.ru/jour/article/view/289/302; Hindricks G., Potpara T., Dagres N., Arbelo E., Bax J., Blomström-Lundqvist C. et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373–498. https://doi.org/10.1093/eurheartj/ehaa612.; Durmaz E., Karpuz M.H., Bilgehan K., Ikitimur B., Ozmen E., Ebren C. et al. Left atrial thrombus in patients with atrial fibrillation and under oral anticoagulant therapy; 3-D transesophageal echocardiographic study. Int J Cardiovasc Imaging. 2020;36(6):1097–1103. https://doi.org/10.1007/s10554-020-01811-x.; Göldi T., Krisai P., Knecht S., Aeschbacher S., Spies F., Zeljkovic I. et al. Prevalence and Management of Atrial Thrombi in Patients With Atrial Fibrillation Before Pulmonary Vein Isolation. JACC Clin Electrophysiol. 2019;5(12):1406–1414. https://doi.org/10.1016/j.jacep.2019.09.003.; Кривошеев Ю.С., Башта Д.И., Красильникова С.Ю., Виленский Л.И., Колесников В.Н., Чуков С.З., Романов А.Б. Тромбоз ушка левого предсердия при фибрилляции предсердий – современное состояние проблемы. Вестник аритмологии. 2019;26(4):13–20. https://doi.org/10.35336/VA-2019-4-13-20.; Гебекова З.А., Иванов И.И., Асамбаева А., Скрипка А.И., Соколова А.А., Напалков Д.А., Вуймо Т.А. Тест «Тромбодинамика» в оценке риска тромбообразования у пациентов с фибрилляцией предсердий, получающих прямые оральные антикоагулянты. Рациональная фармакотерапия в кардиологии. 2022;18(5):544–552. https://doi.org/10.20996/1819-6446-2022-09-07.; Kolekar S., Munjewar Ch., Sharma S. Dabigatran for left ventricular thrombus. Indian Heart Journal. 2015;67:495–496. https://doi.org/10.1016/j.ihj.2015.06.010.; Vidal A., Vanerio G. Dabigatran and left atrial appendage thrombus. J Thromb Thrombolysis. 2012;34:545–547. https://doi.org/10.1007/s11239-012-0747-1.; Takasugi J., Yamagami H., Okata T., Toyoda K., Nagatsuka K. Dissolution of the Left Atrial Appendage Thrombus with Rivaroxaban Therapy. Cerebrovasc Dis. 2013;36:322–323. https://doi.org/10.1159/000354315.; Hammerstingl C., Pötzsch B., Nickenig G. Resolution of giant left atrial appendage thrombus with rivaroxaban. Thromb Haemost. 2013;109:583–584. https://doi.org/10.1160/TH12-11-0821.; Kawakami T., Kobayakawa H., Ohno H., Tanaka N., Ishihara H. Resolution of left atrial appendage thrombus with apixaban. Thromb J. 2013;11(1):26. https://doi.org/10.1186/1477-9560-11-26.; Yildirim E., Kalkan K., Ipek E., Demirelli S., Ermiş E. Successful resolution of left ventricular thrombus with apixaban treatment. Int J Cardiovasc Acad. 2016;2(2):57–58. https://doi.org/10.1016/j.ijcac.2015.12.004.; Lip G.Y., Hammerstingl C., Marin F., Cappato R., Meng I.L., Kirsch B. et al. Left atrial thrombus resolution in atrial fibrillation or flutter: Results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF). Am Heart J. 2016;178:126–134. https://doi.org/10.1016/j.ijcac.2015.12.004.; Zoppo F., Brandolino G., Berton A., Frigato N., Michieletto M., Zanocco A. et al. Predictors of left atrium appendage clot detection despite on-target warfarin prevention for atrial fibrillation. J Interv Card Electrophysiol. 2012;35(2):151–158. https://doi.org/10.1007/s10840-012-9707-0.; Кропачева Е.С., Панченко Е.П., Добровольский А.Б., Атауллаханова А.М., Быкова Е.С., Титаева Е.В., Атьков О.Ю. Длительная терапия непрямыми антикоагулянтами у больных с мерцательной аритмией без поражения клапанов сердца (проспективное наблюдение). Часть I. влияние 12-месячной терапии аценокумаролом на уровень Д-димера, частоту тромбоза и параметры гемодинамики в ушке левого предсердия. Кардиология. 2004;44(6):19–25. Режим доступа: https://pubmed.ncbi.nlm.nih.gov/15211343.; Kawabata M., Goya M., Sasaki T., Maeda S., Shirai Y., Nishimura T. et al. Left Atrial Appendage Thrombi Formation in Japanese Non-Valvular Atrial Fibrillation Patients During Anticoagulation Therapy – Warfarin vs. Direct Oral Anticoagulants. Circ J. 2017;81(5):645–651. https://doi.org/10.1253/circj.CJ-16-1089.; Баландина А.Б., Кольцова Е.М., Шибеко А.М., Купраш А.Д., Атауллаханов Ф.И. Тромбодинамика: новый подход к диагностике нарушений системы гемостаза. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2018;17(4):114–126. https://doi.org/10.24287/1726-1708-2018-17-4-114-126.; Vuimo T., Belikov E., Litinskaya O. Efficiency of Thrombodynamics for Analysis of Hemostasis in Case of Transitory Ischemic Attack after Radio-frequency Ablation in a Patient with Paroxysmal Atrial Fibrillation. Am J Med Case Rep. 2015;3(10):333–337. https://doi.org/10.12691/ajmcr-3-10-8.; Balandina A.N., Serebriyskiy I.I., Poletaev A.V., Polokhov D., Gracheva M., Koltsova E. et al. Thrombodynamics-A new global hemostasis assay for heparin monitoring in patients under the anticoagulant treatment. PloS ONE. 2018;13(6):е0199900. https://doi.org/10.1371/journal.pone.0199900.; Sinauridze E.I., Vuimo T.A., Tarandovskiy I.D., Ovsepyan R., Surov S., Korotina N. et al. Thrombodynamics, a new global coagulation test: Measurement of heparin efficiency. Talanta. 2018;180:282–291. https://doi.org/10.1016/j.talanta.2017.12.055.; Рубаненко А.О., Рубаненко О.А., Дьячков В.А., Щукин Ю.В. Роль D-димера в прогнозировании риска инсульта у больных с фибрилляцией предсердий. Гематология и трансфузиология. 2022;67(2):261–266. https://doi.org/10.35754/0234-5730-2022-67-2-261-266.; https://www.aterotromboz.ru/jour/article/view/289
-
9
Autoren: et al.
Quelle: Rational Pharmacotherapy in Cardiology; Vol 18, No 5 (2022); 600-605 ; Рациональная Фармакотерапия в Кардиологии; Vol 18, No 5 (2022); 600-605 ; 2225-3653 ; 1819-6446
Schlagwörter: апиксабан, atrial fibrillation, dabigatran, rivaroxaban, apixaban, фибрилляция предсердий, дабигатран, ривароксабан
Dateibeschreibung: application/pdf
Relation: https://www.rpcardio.com/jour/article/view/2829/2367; Ghoshal K., Bhattacharyya M. Overview of platelet physiology: its hemostatic and nonhemostatic role in disease pathogenesis. Scientific World Journal 2014; 2014:781857.DOI:10.1155/2014/781857; Koupenova M., Clancy L., Corkrey H., et al. Circulating Platelets as Mediators of Immunity, Inflammation, and Thrombosis. Circ Res. 2018;122:337-351.DOI:10.1161/ CIRCRESAHA. 117.310795; Connolly S., Ezekowitz M., Yusuf S., et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2009;361:1139-1151. DOI:10.1056/NEJMoa0905561.; Patel M., Mahaffey K., Garg J., et al. Rivaroxaban versus Warfarin in Nonval-vular Atrial Fibrillation. N Engl J Med 2011;365:883-891. DOI:10.1056/NEJMoa1009638; Granger C., Alexander J., McMurray J., et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2011;365:981-992. DOI:10.1056/NEJMoa1107039; Park J., Cha M.J., Choi Y.J., et al. Prognostic efficacy of platelet count in patients with nonvalvular atrial fibrillation. Heart Rhythm 2019;16:197-203. DOI:10.1016/j.hrthm.2018.08.023; George J.N., Aster R.H. Drug-induced thrombocytopenia: pathogenesis, evaluation, and management. Hematology (Am Soc Hematol Educ Program). 2009:153-158. DOI:10.1182/asheducation-2009.1.153; AL-Nouri Z.I., George J.N. Drug-induced thrombocytopenia. An updated systematic review, 2012. Drug Saf 2012;35:693-4. DOI:10.2165/11633310-000000000-00000; Bonaccio M., Di Castelnuovo A., Costanzo S., et al. Age- and sex-based ranges of platelet count and causespecific mortality risk in an adult general population: prospective findings from the Moli-sani study. Platelets. 2018;29:312-315 DOI: 0.1080/09537104.2017.1411584; Hindricks G., Potpara T., Dagres N., et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) European Heart Journal 2020 Doi:10.1093/eurheartj/ehaa612; Greinacher A. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med. 2015;373(3):252-261. DOI:10.1056/NEJMcp1411910; Erdem G.U., Dogan M., Demirci N.S., et al. Oxaliplatin-induced acute thrombocytopenia. J Cancer Res Ther. 2016;12(2):509-514. DOI:10.4103/0973-1482.154056.; Fountain E.M., Arepally G.M. Etiology and complications of thrombocytopenia in hospitalized medical patients. J Thromb Thrombolysis. 2017;43:429-436 DOI:10.1007/s11239-016-1467-8; Mc Carthty С., Steg P., Bhatt D. The management of antiplatelet therapy in acute coronary syndrome patients with thrombocytopenia: a clinical conundrum. Eur Heart J. 2017; 38: 3488-3492 DOI:10.1093/eurheartj/ehx531; Yadav M., Genereux P., Giustino G., et al. Effect of baseline thrombocytopenia on ischemic outcomes in patients with acute coronary syndromes who undergo percutaneous coronary intervention. Can J Cardiol. 2016;32:226-233. DOI:10.1016/j.cjca.2015.05.020; Janion-Sadowska A., Papuga-Szela E., Łukaszuk R., et al. Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Thrombocytopenia. Cardiovasc Pharmacol. 2018 Sep;72(3):153-160. DOI:10.1097/FJC.0000000000000607; Pastori D., Antonucci E., Violi.F., et al. Thrombocytopenia and Mortality Risk in Patients With Atrial Fibrillation: An Analysis From the START Registry. Journal of the American Heart Association. 2019;8(21):e012596. DOI 10.1161/JAHA.119.012596.; Michowitz Y., Klempfner R., Shlomo N., et al. Thrombocytopenia and thrombocytosis are associated with different outcome in atrial fibrillation patients on anticoagulant therapy. 2019. PLOS ONE 14(11): e0224709. DOI:10.1371/journal.pone.0224709; Kalabalik J., Rattinger G., Sullivan J., et al. Use of nonvitamin K antagonist oral anticoagulants in special patient populations with nonvalvular atrial fibrillation: a review of the literature and application to clinical practice. Drugs 2015;75:979-998. DOI:10.1007/s40265-015-0405-y; Deidda A., Rapallo M., Sofia M., et al. Thrombocytopenia possibly induced by dabigatran: a case report. Aust J Pharm. 2015;3:1000170. DOI:10.4172/2329-6887.1000170; Naranjo С.A., Busto U., Sellers E.M., et al. A method for estimating the probability of adverse drug reactions. Clin. Pharmacol. Ther., 1981;30:239-45 DOI:10.1038/clpt.1981.154; Kang H.G., Lee S.J., Chung J.Y., et al. BMC Neurology 2017; 17:124-129 DOI:10.1186/s12883-017-0900-8; U.S. Food and Drug Administration. 2018. Potential Signals of Serious Risks/New Safety Information Identified from the FDA Adverse Event Reporting System (FAERS): fda.gov/drugs/questions-and-answersfdas-adverse-event-reporting-system-faers/july-september-2017-potential-signals-serious-risksnew-safe ty-information-identified-fda-adverse.; Mima Y., Sangatsuda Y., Yasaka M., et al. Acute thrombocytopenia after initiating anticoagulation with rivaroxaban Intern Med. 2014;53(21):2523-7. DOI:10.2169/internalmedicine.53.2890; He X.Y., Bai Y. Acute thrombocytopenia after anticoagulation with rivaroxaban: A case report. World J Clin Cases. 2020;8(5):928-931. DOI:10.12998/wjcc.v8.i5.928.; ELIQUIS (apixaban). Product Monograph. ELIQUIS (apixaban). 2019. Montreal, Canada H4S 0A4 www.bmscanada.ca; Snellgrove O. Case report: apixaban-induced thrombocytopenia. Clinical Case Reports 2017; 5(3): 268-269 DOI:10.1002/ccr3.809; Sadaka S. Thrombocytopenia: A possible side effect of apixaban. Clin Case Rep. 2019;7:2543-2544 DOI:10.1002/ccr3.2532; https://www.rpcardio.com/jour/article/view/2829
-
10
Autoren:
Quelle: Rational Pharmacotherapy in Cardiology; Vol 18, No 3 (2022); 332-341 ; Рациональная Фармакотерапия в Кардиологии; Vol 18, No 3 (2022); 332-341 ; 2225-3653 ; 1819-6446
Schlagwörter: дабигатран, direct oral anticoagulants, apixaban, rivaroxaban, dabigatran, прямые пероральные антикоагулянты, апиксабан, ривароксабан
Dateibeschreibung: application/pdf
Relation: https://www.rpcardio.com/jour/article/view/2756/2322; Sarah S. The pharmacology and therapeutic use of dabigatran etexilate. J Clin Pharmacol. 2013;53(1):113. DOI:10.1177/0091270011432169.; Wong PC, Crain EJ, Xin B, et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost. 2008;6(5):820-9. DOI:10.1111/j.15387836.2008.02939.x.; Chan NC, Hirsh J, Ginsberg JS, Eikelboom JW. Betrixaban (PRT054021): pharmacology, dose selection and clinical studies. Future Cardiol. 2014;10(1):43-52. DOI:10.2217/fca.13.98.; Corsini A, Ferri N, Proietti M, Boriani G. Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice. Drugs. 2020;80(11):1065-83. DOI:10.1007/s40265-020-01328-6.; Kvasnicka T, Malikova I, Zenahlikova Z, et al. Rivaroxaban - Metabolism, Pharmacologic Properties and Drug Interactions. Curr Drug Metab. 2017;18(7):636-42. DOI:10.2174/1389200218666170518165443.; Foerster KI, Hermann S, Mikus G, Haefeli WE. Drug-Drug Interactions with Direct Oral Anticoagulants. Clin Pharmacokinet. 2020;59(8):967-80. DOI:10.1007/s40262-020-00879-x.; Connolly SJ, Milling TJ Jr, Eikelboom JW, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med. 2016;375(12):1131-41. DOI:10.1056/NEJMoa1607887.; Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. N Engl J Med. 2017;377(5):431-41. DOI:10.1056/NEJMoa1707278.; Reilly PA, Lehr T, Haertter S, et al.; RE-LY Investigators. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol. 2014;63(4):321-8. DOI:10.1016/j.jacc.2013.07.104.; Ruff CT, Giugliano RP, Braunwald E, et al. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015;385(9984):2288-95. DOI:10.1016/S0140-6736(14)61943-7.; Herink MC, Zhuo YF, Williams CD, DeLoughery TG. Clinical Management of Pharmacokinetic Drug Interactions with Direct Oral Anticoagulants (DOACs). Drugs. 2019;79(15):1625-34. DOI:10.1007/s40265-019-01183-0.; Connolly SJ, Ezekowitz MD, Yusuf S, et al.; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-51. DOI:10.1056/NEJMoa0905561. Erratum in: N Engl J Med. 2010;363(19):1877.; Granger CB, Alexander JH, McMurray JJ, et al.; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-92. DOI:10.1056/NEJMoa1107039.; Giugliano RP, Ruff CT, Braunwald E, et al.; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093-104. DOI:10.1056/NEJMoa1310907.; Patel MR, Mahaffey KW, Garg J, et al.; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-91. DOI:10.1056/NEJMoa1009638.; Weitz JI, Connolly SJ, Patel I, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010;104(3):633-641. DOI:10.1160/th10-01-0066.; Leil TA, Feng Y, Zhang L, et al. Quantification of apixaban’s therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose. Clin Pharmacol Ther. 2010;88(3):375-382. DOI:10.1038/clpt.2010.106.; Sakaguchi T, Osanai H, Murase Y, et al. Monitoring of anti-Xa activity and factors related to bleeding events: a study in Japanese patients with nonvalvular atrial fibrillation receiving rivaroxaban. J Cardiol. 2017;70(3):244-9. DOI:10.1016/j.jjcc.2016.11.013.; Carnicelli AP, Hong H, Connolly SJ, et al.; COMBINE AF (A Collaboration Between Multiple Institutions to Better Investigate Non-Vitamin K Antagonist Oral Anticoagulant Use in Atrial Fibrillation) Investigators. Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network MetaAnalyses of Randomized Clinical Trials With Interaction Testing by Age and Sex. Circulation. 2022;145(4):242-55. DOI:10.1161/CIRCULATIONAHA.121.056355.; Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955-962. DOI:10.1016/S0140-6736(13)62343-0.; Almutairi AR, Zhou L, Gellad WF, et al. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses. Clin Ther. 2017;39(7):1456-78.e36. DOI:10.1016/j.clinthera.2017.05.358.; Piccini JP, Hellkamp AS, Washam JB, et al. Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation. Circulation. 2016;133(4):352-60. DOI:10.1161/CIRCULATIONAHA.115.018544.; Focks JJ, Brouwer MA, Wojdyla DM, et al. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. BMJ. 2016;353:i2868. DOI:10.1136/bmj.i2868.; Harskamp RE, Teichert M, Lucassen WAM, et al. Impact of Polypharmacy and P-Glycoprotein- and CYP3A4-Modulating Drugs on Safety and Efficacy of Oral Anticoagulation Therapy in Patients with Atrial Fibrillation. Cardiovasc Drugs Ther. 2019;33(5):615-23. DOI:10.1007/s10557-019-06907-8.; Stöllberger C, Finsterer J. Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban. Herz. 2015;40 Suppl 2:140-5. DOI:10.1007/s00059-014-4188-9.; Chang SH, Chou IJ, Yeh YH, et al. Association Between Use of Non-Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation. JAMA. 2017;318(13):1250-9. DOI:10.1001/jama.2017.13883.; Rodrigues AD. Prioritization of clinical drug interaction studies using in vitro cytochrome P450 data: proposed refinement and expansion of the "rank order" approach. Drug Metab Lett. 2007;1(1):31-5. DOI:10.2174/187231207779814247.; Wiggins BS, Dixon DL, Neyens RR, et al. Select Drug-Drug Interactions With Direct Oral Anticoagulants. J Am Coll Cardiol. 2020;75:1341-50. DOI:10.1016/j.jacc.2019.12.068.; Cheong EJY, Goh JJN, Hong Y, et al. Rivaroxaban With and Without Amiodarone in Renal Impairment. J Am Coll Cardiol. 2018;71(12):1395-7. DOI:10.1016/j.jacc.2018.01.044.; Flaker G, Lopes RD, Hylek E, et al.; ARISTOTLE Committees and Investigators. Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. J Am Coll Cardiol. 2014;64(15):1541-50. DOI:10.1016/j.jacc.2014.07.967.; Steffel J, Giugliano RP, Braunwald E, et al. Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial. Eur Heart J. 2015;36(33):2239-45. DOI:10.1093/eurheartj/ehv201.; Steinberg BA, Hellkamp AS, Lokhnygina Y, et al.; ROCKET AF Steering Committee and Investigators. Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial. Heart Rhythm. 2014;11(6):925-32. DOI:10.1016/j.hrthm. 2014.03.006.; Friberg L. Safety of apixaban in combination with dronedarone in patients with atrial fibrillation. Int J Cardiol. 2018;264:85-90. DOI:10.1016/j.ijcard.2018.02.055.; Härtter S, Sennewald R, Nehmiz G, Reilly P. Oral bioavailability of dabigatran etexilate (Pradaxa(®) ) after co-medication with verapamil in healthy subjects. Br J Clin Pharmacol. 2013;75(4):1053-62. DOI:10.1111/j.1365-2125.2012.04453.x.; Frost C, Wang J, Nepal S, et al. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol. 2013;75(2):47687. DOI:10.1111/j.1365-2125.2012.04369.x.; Kim M, Son H, Noh K, et al. Effects of Verapamil and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban. Pharmaceutics. 2019;11(3):133. DOI:10.3390/pharmaceutics11030133.; Greenblatt DJ, Patel M, Harmatz JS, et al. Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection. J Clin Pharmacol. 2018;58(4):533-540. DOI:10.1002/jcph.1040.; Bartlett JW, Renner E, Mouland E, et al. Clinical Safety Outcomes in Patients With Nonvalvular Atrial Fibrillation on Rivaroxaban and Diltiazem. Ann Pharmacother. 2019;53(1):21-7. DOI:10.1177/1060028018795140.; Wiggins BS, Northup A, Johnson D, Senfield J. Reduced Anticoagulant Effect of Dabigatran in a Patient Receiving Concomitant Phenytoin. Pharmacotherapy. 2016;36(2):e5-7. DOI:10.1002/phar.1698.; King PK, Stump TA, Walkama AM, et al. Management of Phenobarbital and Apixaban Interaction in Recurrent Cardioembolic Stroke. Ann Pharmacother. 2018;52(6):605-6. DOI:10.1177/1060028018759938.; Steinberg BA, Shrader P, Thomas L, et al.; ORBIT-AF Investigators and Patients. Off-Label Dosing of NonVitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry. J Am Coll Cardiol. 2016;68(24):2597-604. DOI:10.1016/j.jacc.2016.09.966.; Ruiz Ortiz M, Muñiz J, RañaMíguez P, et al.; FANTASIIA study investigators. Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIIA Registry. Europace. 2018;20(10):1577-83. DOI:10.1093/europace/eux316.; Pattullo CS, Barras M, Tai B, et al. New oral anticoagulants: appropriateness of prescribing in real-world setting. Intern Med J. 2016;46(7):812-8. DOI:10.1111/imj.13118.; Okumura Y, Yokoyama K, Matsumoto N, et al.; The Sakura Af Registry Investigators. Current use of direct oral anticoagulants for atrial fibrillation in Japan: Findings from the SAKURA AF Registry. J Arrhythm. 2017;33(4):289-96. DOI:10.1016/j.joa.2016.11.003.; Yao X, Shah ND, Sangaralingham LR, et al. Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction. J Am Coll Cardiol. 2017;69(23):2779-90. DOI:10.1016/j.jacc.2017.03.600.; Barnes GD, Nallamothu BK, Sales AE, Froehlich JB. Reimagining Anticoagulation Clinics in the Era of Direct Oral Anticoagulants. Circ Cardiovasc Qual Outcomes. 2016;9(2):182-5. DOI:10.1161/CIRCOUTCOMES. 115.002366.; Raval AN, Cigarroa JE, Chung MK, et al. Management of Patients on Non-Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association. Circulation. 2017;135(10):e604-e633. DOI:10.1161/CIR.0000000000000477.; https://www.rpcardio.com/jour/article/view/2756
-
11
Autoren:
Quelle: Aterotromboz = Atherothrombosis; Том 12, № 1 (2022); 84-112 ; Атеротромбоз; Том 12, № 1 (2022); 84-112 ; 2658-5952 ; 2307-1109 ; 10.21518/2307-1109-2022-1
Schlagwörter: дабигатран, COVID-19, radiofrequency ablation, anticoagulant therapy, dabigatran, радиочастотная аблация, терапия антикоагулянтами
Dateibeschreibung: application/pdf
Relation: https://www.aterotromboz.ru/jour/article/view/274/291; https://www.aterotromboz.ru/jour/article/view/274
-
12
Autoren:
Quelle: Евразийский Кардиологический Журнал, Vol 0, Iss 2, Pp 64-82 (2018)
Евразийский кардиологический журналSchlagwörter: anticoagulants, варфарин-индуцированная нефропатия, дабигатран, warfarin-induced nephropathy, Dabigatran, 3. Good health, фибрилляция предсердий, хроническая болезнь почек, RC666-701, Diseases of the circulatory (Cardiovascular) system, atrial fibrillation, dabigatran, chronic kidney disease, антикоагулянты
-
13
Autoren: et al.
Schlagwörter: DABIGATRAN, IDARUCIZUMAB, THROMBOLYTIC THERAPY, SPECIFIC ANTAGONIST, ДАБИГАТРАН, ИДАРУЦИЗУМАБ, ТРОМБОЛИТИЧЕСКАЯ ТЕРАПИЯ, СПЕЦИФИЧЕСКИЙ АНТАГОНИСТ
Dateibeschreibung: application/pdf
Relation: Уральский медицинский журнал. 2021. т. 20. №4; http://elib.usma.ru/handle/usma/6303
Verfügbarkeit: http://elib.usma.ru/handle/usma/6303
-
14
Autoren: et al.
Quelle: Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics); Том 66, № 2 (2021); 21-28 ; Российский вестник перинатологии и педиатрии; Том 66, № 2 (2021); 21-28 ; 2500-2228 ; 1027-4065 ; 10.21508/1027-4065-2021-66-2
Schlagwörter: тромбэктомия, newborns, neonatal thrombosis, hemostasis, heparin, dabigatran, thrombectomy, новорожденные, неонатальные тромбозы, гемостаз, гепарин, дабигатран
Dateibeschreibung: application/pdf
Relation: https://www.ped-perinatology.ru/jour/article/view/1369/1068; Shaik M., Patel D., Mihir B., Chan A.K.C., Paes B. Epidemiology, Diagnosis and Management of Neonatal Thrombosis. Blood 2019; 134: 3656. DOI:10.1182/blood-2019-129914; Szpecht D., Szymankiewicz M., Nowak I., Gadzinowski J Intraventricular hemorrhage in neonates born before 32 weeks of gestation-retrospective analysis of risk factors. Childs Nerv Syst 2016; 32: 1399–1404. DOI:10.1007/s00381-016-3127-x; Bikdeli B., Jiménez D., Hawkins M., Ortíz S., Prandoni P., Brenner B. et al. Rationale, design and methodology of the computerized registry of patients with venous thromboembolism (RIETE). Thromb Haemost 2018; 118(1): 214–224. DOI:10.1160/TH17-07-0511; Sirachainan N., Limrungsikul A., Chuansumrit A., Nuntnarumit P., Thampratankul L., Wangruangsathit S. et al. Incidences, risk factors and outcomes of neonatal thromboembolism, J Matern Fetal Neonatal Med 2018; 31:347–351. DOI:10.1080/14767058.2017.1285892; Haley K.M. Neonatal Venous Thromboembolism. Front Pediatr 2017; 5: 136–142. DOI:10.3389/fped.2017.00136; Sewell E.K., Forman K.R., Wong E.C.C., Gallagher M., Luban N.L.C., Massaro A.N. Thromboelastography in term neonates: an alternative approach to evaluating coagulopathy. Arch. Dis. Child Fetal Neonatal Ed 2017; 102: F79–F84. DOI:10.1136/archdischild-2016-310545; Roshdy E.A. White Blood Cells and Platelets Indices as a Prognostic Factor in Neonatal Sepsis. Case Med Res 2019 https://clinicaltrials.gov/ct2/show/NCT03880305; Koltsova E.M., Balandina A.N., Grischuk K.I., Shpilyuk M.A., Dashkevich N.M., Poletaev A.V. et al. The laboratory control of anticoagulant thromboprophylaxis during the early postpartum period after cesarean delivery. J Perinat Med 2018; 46:251–260. DOI:10.1515/jpm-2016-0333; Khan A.O., Pike J.A. Super-resolution imaging and quantification of megakaryocytes and platelets. Platelets 2020; 1: 1–11. DOI:10.1080/09537104.2020.1732321; Krapivina E.V., Novikova T.V. Functional features of hemostasis in physically weakened newborn piglets and calves. BIO Web of Conferences 2020; 17: 1-5. DOI:10.1051/bioconf/20201700162; Ngo A.T.P., Sheriff J., Rocheleau A.D., Bucher M., Jones K.R., Sepp A.L.I. et al. Assessment of neonatal, cord, and adult platelet granule trafficking and secretion. Platelets 2020; 31(1): 68–78. DOI:10.1080/09537104.2019.1573314; Cott E.V., Smock K., Lippi G. Innovations in Thrombosis and Hemostasis: A Glimpse Towards the Future of Diagnostic Analyzers. Sem Thromb Hemost 2019; 45(3): 225–227. DOI:10.1055/s-0039-1683844; Ferrer-Marin F., Liu Z.J., Gutti R., Sola-Visner M. Neonatal Thrombocytopenia and Megakaryocytopoiesis. Semin Hematol 2010; 47: 281–8. DOI:10.1053/j.seminhema-tol.2010.04.002; Meyer A.D., Rishmawi A.R., Kamucheka R., Lafleur C., Batchinsky A.I., Mackman N. et al. Effect of blood flow on platelets, leukocytes, and extracellular vesicles in thrombosis of simulated neonatal extracorporeal circulation. J Thromb Haemost 2020; 18(2): 399–410. DOI:10.1111/jth.14661; Urban D., Pluthero F., Christensen H., Baidya Sh., Rand M., Das A. et al. Decreased numbers of dense granules in fetal and neonatal platelets. Haematol 2017; 102:e36–8. DOI:10.3324/haematol.2016.152421; Sitaru A.G., Holzhauer S., Speer C.P., Singer D., Obergfell A., Walter U., Grossmann R. Neonatal platelets from cord blood and peripheral blood. Platelets 2005; 16:203–10. DOI: org/10.1080/09537100400016862; Haley K., Recht M., McCarty O. Neonatal platelets: mediators of primary hemostasis in the developing hemostatic system. Pediatr Res 2014; 76: 230–237. DOI:10.1038/pr.2014.87; Monagle P. Slow progress. How do we shift the paradigm of thinking in pediatric thrombosis and anticoagulation? Thromb Res 2019; 173: 186–190. DOI:10.1016/j.thromres.2018.07.016; Kenet G., Cohen O., Bajorat T., Nowak-Göttl U. Insights into neonatal thrombosis. Thromb Res 2019; 181: S33–S36. DOI:10.1016/s0049-3848(19)30364-0; Federici E., Al-Mondhiry H. High risk of thrombosis recurrence in patients with homozygous and compound heterozygous factor V R506Q (Factor V Leiden) and prothrombin G20210A. Thromb Res 2019; 182:75–78. DOI:10.1016/j.thromres.2019.07.030; Черкасова С.В. Гемостаз новорожденных. Практика педиатра 2020; 1:49–52. [Cherkasova S.V. Hemostasis of the newborn. Praktika pediatra 2020; 1:49–52. (in Russ.)]; Heavey E. Screening newborns for critical congenital heart defects. Nursing 2019; 49(1):17–18. DOI:10.1097/01.nurse.0000549738.60681.f8; Koltsova E.M., Balashova E.N., Ignatova A.A., Poletaev A.V., Polokhov D.M., Kuprash A.D. et al. Impaired platelet activity and hypercoagulation in healthy term and moderately preterm newborns during the early neonatal period. Pediatr Res 2019; 85:63–71. DOI:10.1038/s41390-018-0184-8; Yurdakök K., Oran O., Tekinalp G., Dündar S., Yurdakök M. Plasma Protein C and Antithrombin III Levels in Polycythemic Newborns. J Pediatr Hematol Oncol 1989; 6(1):59–61. DOI:10.3109/08880018909014583; Marco A., Marco P. Cerebral Venous Thrombosis in a Pediatric Patient with Antithrombin Deficiency. J Clinical Case Rep Case Stud 2019; 2(1):16–20. DOI:10.29199/2637-9309/cccs.201020; Koltsova E.M., Balandina A.N., Grischuk K.I., Shpilyuk M.A., Seregina E.A., Dashkevich N.M. et al. The laboratory control of anticoagulant thromboprophylaxis during the early postpartum period after cesarean delivery. J Perinat Med 2017; 46(3):251–260. DOI:10.1515/jpm-2016-0333; Nowak-Göttl U., Limperger V., Kenet G., Degenhardt F., Arlt R., Domschikowski J. et al. Developmental hemostasis: A lifespan from neonates and pregnancy to the young and elderly adult in a European white population. Blood Cells Mol Dis 2017; 67: 2–13. DOI:10.1016/j.bcmd.2016.11.012; Lokeshwar M.R., Sachdeva A. Fetal & Neonatal Hematology, Oncology and Immunology. London, Jaypee Brothers Medical Publishers; first edition. 2017; 135–137; Lee J.W., Her S.M., Kim J.H., Lee K.H., Eisenhut M., Park S.J., Shin J.I. D-dimer as a marker of acute pyelonephritis in infants younger than 24 months with urinary tract infection. Pediatr Nephrol 2018; 33(4):631–637. DOI:10.1007/s00467-017-3843-9; Asakura H., Takahashi H., Uchiyama T., Eguchi Y., Okamoto K., Kawasugi K. et al. Proposal for new diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis. Thrombosis J 2016; 14(1): 42. DOI:10.1186/s12959-016-0117-x; Sharma A. Plasma Fibrinogen and D-dimer in Children With Sepsis: A Single-Center Experience. Iran J Pathol 2018; 13(2):272–275. DOI:10.30699/ijp.13.2.272; Stefanov G., Puppala B.L., Pais G., Gulati A. Endothelin-1 levels, and renal function in newborns of various gestational ages. J Neonatal Perinatal Med 2016; 9:145–152. DOI:10.3233/NPM-16915078; El Shemi M.S., Tawfik S., Khafagy S.M., Hamza M.T., Youssef A.M.A. Endothelin 1 as a predictor marker for bronchopulmonary dysplasia in preterm neonates with respiratory distress syndrome. J Neonatal Perinatal Med 2017; 10:79–83. DOI:10.3233/NPM-1653; Sewell E.K., Forman K.R., Wong E.C.C., Gallagher M., Luban N.L.C., Massaro A.N. Thromboelastography in term neonates: an alternative approach to evaluating coagulopathy. Arch Dis Child Fetal Neonatal Ed 2017; 102: F79–84. DOI:10.1136/archdischild-2016-310545; Gracheva M.A., Urnova E.S., Sinauridze E.I., Tarandovskiy I.D., Orel E.B., Poletaev A.V. et al. Thromboelastography, thrombin generation test and thrombodynamics reveal hypercoagulability in patients with multiple myeloma. Leuk Lymphoma 2015; 56: 3418–3425. DOI:10.3109/10428194.2015.1041385; Koltsova E.M., Balashova E.N., Panteleev M.A., Balandina A.N. Laboratory aspects of hemostasis in neonates. Pediatr Hematol Oncol Immunopathol 2018; 17(4): 100–113. DOI:10.24287/1726-1708-2018-17-4-100-113; Strauss T., Elisha N., Ravid B., Rosenberg N., Lubetsky A., Levy-Mendelovich S. et al. Activity of Von Willebrand factor and levels of VWF-cleaving protease (ADAMTS13) in preterm and full-term neonates, Blood Cell Mol Dis 2017; 67: 14–17. DOI:10.1016/j.bcmd.2016.12.013; Mutch N.J., Koikkalainen J.S., Fraser S.R., Duthie K.M., Griffin M., Mitchell J. et al. Model thrombi formed under flow reveal the role of factor XIII-mediated cross-linking in resistance to fibrinolysis. J Thromb Haemost 2010; 8(9): 2017–24. DOI:10.1111/j.1538-7836.2010.03963.x; Bhat R., Monagle P. Anticoagulation in preterm and term neonates: Why are they special? Thromb Res 2020; 187: 113– 121. DOI:10.1016/j.thromres.2019.12.019; Baker-Groberg S.M., Lattimore S., Recht M., McCarty O.J.T., Haley K.M. Assessment of neonatal platelet adhesion, activation, and aggregation. J Thromb Haemost 2016; 14: 815–827. DOI:10.1111/jth.13270; Кольцова Е.М., Балашова Е.Н., Пантелеев М.А., Баландина А.Н. Лабораторные аспекты гемостаза новорожденных. Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2018; 17(4): 100–113. [Kol’cova E.M., Balashova E.N., Panteleev M.A., Balandina A.N. Laboratory aspects of hemostasis in newborns. Voprosy gematologii/onkologii i immunopatologii v pediatrii 2018; 17(4): 100–113. (in Russ.)]; Abentaeva B., Charipova B., Aubakirova B. Clinical case neonatal thrombosis of preterm newborn. J Cllin Med Kaz 2017; 3(45):84–88. DOI:10.23950/1812-2892-JCMK-00481; Darwood R., Berridge D.C., Kessel D.O., Robertson I., Forster R. Surgery versus thrombolysis for initialmanagement of acute limb ischaemia. Cochrane Database Syst Rev 2018; 8: CD002784. DOI:10.1002/14651858.CD002784.pub3; Федеральные клинические рекомендации по диагностике, профилактике и лечению тромбозов у детей и подростков. ФГБУ «ФНКЦ ДГОИ имени Дмитрия Рогачева» Минздрава России и Национальное общество детских гематологов, онкологов России 2015 г. [Federal clinical guidelines for the diagnosis, prevention and treatment of thrombosis in children and adolescents. FSBI “FNKTS DPOI named after Dmitry Rogachev” of the Ministry of Health of Russia and the National Society of Pediatric Hematologists, Oncologists of Russia 2015; http://nodgo.org/sites/default/files/34.%20Тромбозы.pdf]; Moustafa F., Pesavento R., Micco P.D., González-Martínez J., Quintavalla R., Peris M.l. et al. Real-life use of anticoagulants in venous thromboembolism, with focus on patients with exclusion criteria for direct oral anticoagulants. Clin. Pharmacol. Ther. 2018; 103: 684–691. DOI:10.1002/cpt.781; Monagle P., Cuello C.A., Augustine C., Bonduel M., Brandão L.R., Capman T. et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism. Blood Adv 2018; 2: 3292–3316. DOI:10.1182/bloodadvances.2018024786; Iijima S. Seasonal and meteorological associations of vitamin K-dependent coagulation factors in 1-month-old infants. Blood Coagul Fibrinols 2020; 31(3): 233–236. DOI:10.1097/mbc.0000000000000896; Brett O.F., Brett C.N., Chin P.K.L. The effect of routine preoperative interruption of dabigatran therapy on coagulation parameters and dabigatran plasma levels in a mixed surgical population. Anaesth Intens Care 2019; 47(2): 183–188. DOI:10.1177/0310057x19841009; Dieffenbach B. V., Nath B.D., Tracy E.T., Kim H.B. Management of symptomatic neonatal aortic thrombosis: When is surgery indicated? J Pediatr Surg Case Rep 2019; 47: 1–4. DOI:10.1016/j.epsc.2019.101247; Utne K.K., Dahm A., Wik H.S., Jelsness-Jørgensen L.P., Sandset P.M., Ghanima W. Rivaroxaban versus warfarin for the prevention of post-thrombotic syndrome. Thromb Res 2018; 163: 6–11. DOI:10.1016/j.thromres.2018.01.013; Houghton D.E., Casanegra A., Peterson L.G., Cochuyt J., Hodge D.O., Vlazny D. et al. Treatment of upper extremity deep vein thrombosis with apixaban and rivaroxaban. Blood 2019; 134(1): 2158. DOI:10.1182/blood-2019-125099; Mantis C., Alexopoulos D. Antithrombotic treatment in atrial fibrillation patients undergoing PCI: Is dual therapy the winner? Thromb Res 2019; 176: 133–139. DOI:10.1016/j.thromres.2019.02.022; Sol J.S., Loo M., Boerma M., Bergman K.A., Donker A.E., van der Hoeven M.A. et al. NEOnatal Central-venous Line Observational study on Thrombosis (NEOCLOT): evaluation of a national guideline on management of neonatal catheter-related thrombosis. BMC Pediatr 2018; 18(1): 84. DOI:10.1186/s12887-018-1000-7; Аксенов Д.В., Чусов К.П., Рябкова М.Г., Свирин П.В., Кругляков А.Ю., Дубенок С.Ю. Тромболитическая терапия у новорожденного с массивным артериовенозным тромбозом. Опыт Морозовской детской городской клинической больницы. Неонатология: новости, мнения, обучение 2019; 7(2): 59–67. [Aksenov D.V., Chusov K.P., Ryabkova M.G., Svirin P.V., Kruglyakov A.Yu., Dubenok S.Yu. Thrombolytic therapy in a newborn with massive arteriovenous thrombosis. Experience of the Morozov Children’s City Clinical Hospital. Neonatologiya: novosti, mneniya, obuche- nie 2019; 7(2): 59–67. (in Russ.)]; Puangpunngam N. Endovascular thrombectomy versus open surgical thrombectomy for thrombosed arteriovenous hemodialysis graft. Siriraj Med J 2019; 71(6): 491–498. DOI:10.33192/smj.2019.73; Cournoyer-Rodrigue J., Bui T.B., Gilbert P., Soulez G., Perreault P., Bouchard L. et al. Percutaneous Thrombectomy with the JETi8 Peripheral Thrombectomy System for the Treatment of Deep Vein Thrombosis. J Vascular and Interventional Radiology 2020; 31(3): 444–453. DOI: org/10.1016/j.jvir.2019.10.022; Nurmeev I.N., Kostromin A.A., Okoye B. Treatment of the newborn with a floating thrombus in the right atrium: case report. Russ Open Med J 2019; 8:e0111; Ivlev D.A., Shirinli S.N., Guria K.G., Uzlova S.G., Guria G.T. Control of fibrinolytic drug injection via real-time ultrasonic monitoring of blood coagulation. PLOS ONE 2019: 1–17. DOI:10.1371/journal.pone.0211646
-
15
Autoren: et al.
Quelle: Rational Pharmacotherapy in Cardiology; Vol 17, No 1 (2021); 146-152 ; Рациональная Фармакотерапия в Кардиологии; Vol 17, No 1 (2021); 146-152 ; 2225-3653 ; 1819-6446
Schlagwörter: dabigatran etexilate, dabigatran, pharmacokinetics, effectiveness, safety, CES1, ABCB1, UGT2B15, дабигатрана этексилат, дабигатран, фармакокинетика, фармакогенетика, эффективность, безопасность
Dateibeschreibung: application/pdf
Relation: https://www.rpcardio.com/jour/article/view/2400/2126; Heit J.A. Venous thromboembolism: disease burden, outcomes and risk factors. J Thromb Haemost. 2005; 3(8):1611-7. DOI:10.1111/j.1538-7836.2005.01415.x.; Feigin V.L., Lawes C.M., Bennett D.A., et al. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol. 2009; 8(4):355-69. DOI:10.1016/S1474-4422(09)70025-0.; Falck-Ytter Y., Francis C.W., Johanson N.A, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e278S. DOI:10.1378/chest.11-2404.; Pedersen A.B., Mehnert F., Sorensen H.T., et al. The risk of venous thromboembolism, myocardial infarction, stroke, major bleeding and death in patients undergoing total hip and knee replacement. Bone Joint J. 2014;96:479-4805. DOI:10.1302/0301-620x.96b4.33209.; Ageno W., Gallus A.S., Wittkowsky A., et al. Oral anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2):44-88. DOI:10.1378/chest.11-2292.; Ezekowitz M.D., Bridgers S.L., James K.E., et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med. 1992;327(20):1406-12. DOI:10.1056/NEJM199211123272002.; Simonneau G., Sors H., Charbonnier B., et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire. N Engl J Med. 1997;337(10):663-9. DOI:10.1056/NEJM199709043371002.; Holford N.H. Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the doseeffect relationship. Clin Pharmacokinet. 1986;11(6):483-504. DOI:10.2165/00003088-198611060-00005.; Shendre A., Parmar G.M., Dillon C., et al. Influence of Age on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage. Pharmacotherapy. 2018;38(6):588-96. DOI:10.1002/phar.2089.; Shatzel J.J., Daughety M.M., Prasad V., DeLoughery T.G. Reversal of warfarin era thinking. J Intern Med. 2018;283(4):408-10. DOI:10.1111/joim.12697.; Barnes G.D. Predicting the Quality of Warfarin Therapy: Reframing the Question. Thromb Haemost. 2019;119(4):509-11. DOI:10.1055/s-0039-1681060.; Wu A.H. Pharmacogenomic-guided dosing for warfarin: too little too late? Per Med. 2018;15(2):71- 3. DOI:10.2217/pme-2017-0080.; Schulman S., Kearon C., Kakkar A.K., et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342-52. DOI:10.1056/NEJMoa0906598.; Stangier J., Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost. 2009;15(1):9-16. DOI:10.1177/1076029609343004.; Drugs.com. FDA Approves Pradaxa [cited by Jun 15, 2020]. Available from: www.drugs.com/newdrugs/fda-approves-pradaxa-prevent-stroke-atrial-fibrillation-2370.html.; Drugs.com. FDA Approves Pradaxa for deep venous thrombosis and pulmonary embolism [cited by Jun 15, 2020]. Available from: www.drugs.com/newdrugs/fda-approves-pradaxa-deep-venousthrombosis-pulmonary-embolism-4030.html.; Drugs.com. FDA Approves Pradaxa for prophylaxis of deep venous thrombosis and pulmonary embolism after hip replacement surgery [cited by Jun 15, 2020]. Available from: www.drugs.com/newdrugs/fda-approves-pradaxa-prophylaxis-deep-venous-thrombosis-pulmonary-embolism-after-hip-replacement-4304.html.; Stangier J., Rathgen K., Stähle H., et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64(3):292-303. DOI:10.1111/j.1365-2125.2007.02899.x.; Hankey G.J., Eikelboom J.W. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation. 2011;123(13):1436-50. DOI:10.1161/CIRCULATIONAHA.110.004424.; Goldsack N.R., Chambers R.C., Dabbagh K., Laurent G.J. Thrombin. Int J Biochem Cell Biol. 1998;30(6):641-6. DOI:10.1016/s1357-2725(98)00011-9.; Davie E.W., Kulman J.D. An overview of the structure and function of thrombin. Semin Thromb Hemost. 2006;32(1):3-15. DOI:10.1055/s-2006-939550.; Comin J., Kallmes D.F. Dabigatran (Pradaxa). American Journal of Neuroradiology. 2002;33(3):426- 8. DOI:10.3174/ajnr.a3000.; Gelosa P., Castiglioni L., Tenconi M., et al. Pharmacokinetic drug interactions of the non-vitamin K antagonist oralanticoagulants (NOACs). Pharmacol Res. 2018;135:60-79. DOI:10.1016/j.phrs.2018.07.016.; Comuth W.J., Henriksen L.Ø., van de Kerkhof D., et al. Comprehensive characteristics of the anticoagulant activity of dabigatran in relation to its plasma concentration. Thromb Res. 2018;164:32- 39. DOI:10.1016/j.thromres.2018.02.141.; Antonijevic N.M., Zivkovic I.D., Jovanovic L.M., et al. Dabigatran - metabolism, pharmacologic properties and drug interactions. Curr Drug Metab. 2017;18(7):622-35. DOI:10.2174/1389200218666170427113504.; Fawzy A.M., Lip G.Y.H. Pharmacokinetics and pharmacodynamics of oral anticoagulants used in atrial fibrillation. Expert Opin Drug Metab Toxicol. 2019;15(5):381-98. DOI:10.1080/17425255.2019.1604686.; Инструкция по медицинскому применению лекарственного препарата Прадакса® 150 мг. Регистрационное удостоверение: ЛП-000872 от 21.10.2016 [цитировано 20.10.2020]. Доступно на: http://grls.rosminzdrav.ru/grls.aspx?s=прадакса&m=tn; Bouhajib M., Tayab Z. A Pharmacokinetic evaluation of Dabigatran etexilate, total dabigatran, and unconjugated Dabigatran following the administration of Dabigatran etexilate mesylate capsulesin healthy male and female subjects. Drug Res (Stuttg). 2020;70(1):33-40. DOI:10.1055/a-1025-0119.; Dimatteo C., D'Andrea G., Vecchione G., et al. Pharmacogenetics of dabigatran etexilate interindividual variability. Thromb Res. 2016;144:1-5. DOI:10.1016/j.thromres.2016.05.025.; Satoh T., Hosokawa M. Structure, function and regulation of carboxylesterases. Chem Biol Interact. 2006;162(3):195-211. DOI:10.1016/j.cbi.2006.07.001.; Ghosh S., Natarajan R. Cloning of the human cholesteryl ester hydrolase promoter: identification of functional peroxisomal proliferator-activated receptor responsive elements. Biochem Biophys Res Commun. 2001;284(4):1065-70. DOI:10.1006/bbrc.2001.5078.; Shi J., Wang X., Nguyen J.H., et al. Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender. Biochem Pharmacol. 2016;119:76-84. DOI:10.1016/j.bcp.2016.09.003.; Chen Z., Shi T., Zhang L., et al. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016;370(1):153-64. DOI:10.1016/j.canlet.2015.10.010.; Gouin-Thibault I., Delavenne X., Blanchard A., et al. Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin. J Thromb Haemost. 2017;15(2):273-283. DOI:10.1111/jth.13577.; Aszalos A. Drug-drug interactions affected by the transporter protein, P-glycoprotein (ABCB1, MDR1) I. Preclinical aspects. Drug Discov Today. 2007;12(19-20):833-7. DOI:10.1016/j.drudis.2007.07.022.; Ebner T., Wagner K., Wienen W. Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity. Drug Metab Dispos. 2010;38(9):1567-75. DOI:10.1124/dmd.110.033696.; UniProt. UDP-glucuronosyltransferase 2B15. UniProt Knowledgebase [cited by Jun 15, 2020]. Available from: www.uniprot.org/uniprot/P54855.; Chung J.Y., Cho J.Y., Yu K.S., et al. Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers. Clin Pharmacol Ther. 2005;77(6):486‐494. DOI:10.1016/j.clpt.2005.02.006.; Bernier M., Lancrerot S.L., Rocher F., et al. Major bleeding events in octagenarians associated with drug interactions between dabigatran and P-gp inhibitors. J Geriatr Cardiol. 2019;16(11):806-11. DOI:10.11909/j.issn.1671-5411.2019.11.002.; Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-51. DOI:10.1056/NEJMoa0905561.; Daud A.N., Bergman J.E., Bakker M.K., et al. P-Glycoprotein-mediated drug interactions in pregnancy and changes in the risk of congenital anomalies: a case-reference study. Drug Saf. 2015;38(7):651- 9. DOI:10.1007/s40264-015-0299-3.; Paré G., Eriksson N., Lehr T., et al. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation. 2013;127(13):1404-12. DOI:10.1161/CIRCULATIONAHA.; Сычев Д.А., Абдуллаев Ш.П., Мирзаев К.Б., и др. Генетические детерминанаты безопасности применения прямого ингибитора тромбина среди этнических групп Российской Федерации. Биомедицина. 2019; (1):78-94. DOI:10.33647/2074-5982-15-1-78-94.; Сычев Д.А., Леванов А.Н., Шелехова Т.В., Шелехова Т.В., и др. Влияние полиморфизма генов abcb1 и ces1 на уровни равновесных концентраций дабигатрана у пациентов после эндопротезирования коленного сустава. Атеротромбоз. 2018;(1):122-30. DOI:10.21518/2307-1109-2018-1-122-130.; He X., Hesse L.M., Hazarika S., et al. Evidence for oxazepam as an in vivo probe of UGT2B15: oxazepam clearance is reduced by UGT2B15 D85Y polymorphism but unaffected by UGT2B17 deletion. Br J Clin Pharmacol. 2009;68(5):721-30. DOI:10.1111/j.1365-2125.2009.03519.x.; Court M.H., Zhu Z., Masse G., et al. Race, gender, and genetic polymorphism contribute to variability in acetaminophen pharmacokinetics, metabolism, and protein-adduct concentrations in healthy African-American and European-American volunteers. J Pharmacol Exp Ther. 2017;362(3):431- 40. DOI:10.1124/jpet.117.242107.; Савельева М.И., Урванцева И.А., Игнатова А.К., и др. Фармакогенетические особенности II фазы биотрансформации тамоксифена: систематический обзор. Фармакогенетика и Фармакогеномика. 2017;(1):10-5.; Ethell B.T., Anderson G.D., Burchell B. The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP-glucuronosyltransferases. Biochem Pharmacol. 2003;65(9):1441-9. DOI:10.1016/s0006-2952(03)00076-5.; Stringer F., Ploeger B.A., DeJongh J., et al. Evaluation of the impact of UGT polymorphism on the pharmacokinetics and pharmacodynamics of the novel PPAR agonist sipoglitazar. J Clin Pharmacol. 2013;53(3):256-63. DOI:10.1177/0091270012447121.; https://www.rpcardio.com/jour/article/view/2400
-
16
Autoren: et al.
Quelle: Rational Pharmacotherapy in Cardiology; Vol 17, No 1 (2021); 62-72 ; Рациональная Фармакотерапия в Кардиологии; Vol 17, No 1 (2021); 62-72 ; 2225-3653 ; 1819-6446
Schlagwörter: atrial fibrillation, glomerular filtration rate, amiodarone, dabigatran, rivaroxaban, apixaban, фибрилляция предсердий, скорость клубочковой фильтрации, амиодарон, дабигатран, ривароксабан, апиксабан
Dateibeschreibung: application/pdf
Relation: https://www.rpcardio.com/jour/article/view/2389/2113; Chugh S.S., Havmoeller R., Narayanan K. et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129:837-847. DOI:10.1161/CIRCULATIONAHA.113.005119.; Eckardt K.U., Coresh J., Devuyst O., et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet. 2013;382:158-69. DOI:10.1016/S0140-6736(13)60439-0.; Boriani G., Savelieva I., Dan G.A., et al. Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making - a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace. 2015;17:1169-96. DOI:10.1093/europace/euv202.; Friberg L., Hammar N., Ringh M., et al. Stroke prophylaxis in atrial fibrillation: who gets it and who does not? Report from the Stockholm cohort-study on atrial fibrillation (SCAF-study). Eur Heart J. 2006;27(16):1954-64. DOI:10.1093/eurheartj/ehl146.; Christiansen C.F., Schmidt M., Lamberg A.L., et al. Kidney disease and risk of venous thromboembolism: a nationwide population-based case-control study. J Thromb Haemost. 2014;12:1449-54. DOI:10.1111/jth.12652.; Pavord S., Myers B. Bleeding and thrombotic complications of kidney disease. Blood Rev. 2011;25:271-8. DOI:10.1016/j.blre.2011.07.001.; Jun M., James M.T., Manns B.J., et al. The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study. BMJ. 2015;350:h246. DOI:10.1136/bmj.h246.; Luo J.C., Leu H.B., Hou M.C., et al. Nonpeptic ulcer, nonvariceal gastrointestinal bleeding in hemodialysis patients. Am J Med. 2013;126:e25-e32. DOI:10.1016/j.amjmed.2012.09.010.; Kirchhof P., Benussi S., Kotecha D., et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18(11):1609-78. DOI:10.1093/eurheartj/ehw210.; Loo S.Y., Dell’Aniello S., Huiart L., Renoux C. Trends in the prescription of novel oral anticoagulants in UK primary care. Br J Clin Pharmacol. 2017;83:2096-106. DOI:10.1111/bcp.13299.; Desai N.R., Krumme A.A., Schneeweiss S., et al. Patterns of initiation of oral anticoagulants in patients with atrial fibrillation - quality and cost implications. Am J Med. 2014;127:1075-82. DOI:10.1016/j.amjmed.2014.05.013.; Watanabe H., Watanabe T., Sasaki S., et al. Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study. Am Heart J. 2009;158:629-36. DOI:10.1016/j.ahj.2009.06.031.; Conen D., Chae C.U., Glynn R.J., et al. Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. JAMA. 2011;305:2080-7. DOI:10.1001/jama.2011.659.; Shih C.J., Ou S.M., Chao P.W., et al. Risks of death and stroke in patients undergoing hemodialysis with new-onset atrial fibrillation: a competing-risk analysis of a nationwide cohort. Circulation. 2016;133:265-72. DOI:10.1161/CIRCULATIONAHA.115.018294.; Bansal N., Fan D., Hsu C.Y., et al. Incident atrial fibrillation and risk of death in adults with chronic kidney disease. J Am Heart Assoc. 2014;3:e001303. DOI:10.1161/JAHA.114.001303.; Friberg L., Benson L., Lip G.Y. Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study. Eur Heart J. 2015;36:297-306. DOI:10.1093/eurheartj/ehu139.; Winkelmayer W.C., Patrick A.R., Liu J., et al. The increasing prevalence of atrial fibrillation among hemodialysis patients. J Am Soc Nephrol. 2011;22:349-57. DOI:10.1681/ASN.2010050459.; Goldstein B.A., Arce C.M., Hlatky M.A., et al. Trends in the incidence of atrial fibrillation in older patients initiating dialysis in the United States. Circulation. 2012;126:2293-301. DOI:10.1161/CIRCULATIONAHA.112.099606.; Chao T.F., Liu C.J., Wang K.L., et al. Incidence and prediction of ischemic stroke among atrial fibrillation patients with end-stage renal disease requiring dialysis. Heart Rhythm. 2014;11:1752-9. DOI:10.1016/j.hrthm.2014.06.021.; Chan P.H., Huang D., Yip P.S., et al. Ischaemic stroke in patients with atrial fibrillation with chronic kidney disease undergoing peritoneal dialysis. Europace. 2016;18:665-71. DOI:10.1093/europace/euv289.; Piccini J.P., Stevens S.R., Chang Y., et al. ROCKET AF Steering Committee and Investigators. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation. 2013;127:224-32. DOI:10.1161/CIRCULATIONAHA.112.107128.; Roldan V., Marin F., Manzano-Fernandez S., et al. Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation? Thromb Haemost. 2013;109:956-60. DOI:10.1160/TH13-01-0054.; Singer D.E., Chang Y., Borowsky L.H., et al. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. J Am Heart Assoc. 2013;2:e000250. DOI:10.1161/JAHA.113.000250.; January C.T., Wann L.S., Alpert J.S., et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:2246-76. DOI:10.1161/CIR.0000000000000665.; Bonde A.N., Lip G.Y., Kamper A.L., et al. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. J Am Coll Cardiol. 2014;64:2471-82. DOI:10.1016/j.jacc.2014.09.051.; Hindricks G., Potpara T., Dagres N., et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2020 Aug 29:ehaa612. DOI:10.1093/eurheartj/ehaa612.; Ha J.T., Badve S.V., Jun M. Recent evidence for direct oral anticoagulants in chronic kidney disease. Curr Opin Nephrol Hypertens. 2019;28(3):251-61. DOI:10.1097/MNH.0000000000000493.; Yang J.Y., Lee T.C., Montez-Rath M.E., et al. Trends in acute nonvariceal upper gastrointestinal bleeding in dialysis patients. J Am Soc Nephrol. 2012;23:495-506. DOI:10.1681/ASN.2011070658.; Hagendorn R., Farkas N., Vincze A., et al. Chronic kidney disease severely deteriorates the outcome of gastrointestinal bleeding: A meta-analysis. World J Gastroenterol. 2017;23:8415-25. DOI:10.3748/wjg.v23.i47.8415.; Granger C.B., Alexander J.H., McMurray J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-92. DOI:10.1056/NEJMoa1107039.; Abraham N.S., Noseworthy P.A., Yao X., et al. Gastrointestinal safety of direct oral anticoagulants: a large population-based study. Gastroenterology. 2017;152:1014-22. DOI:10.1053/j.gastro.2016.12.018.; Padrini R. Clinical pharmacokinetics and pharmacodynamics of direct oral anticoagulants in patients with renal failure. Eur J Drug Metab Pharmacokinet. 2019;44(1):1-12. DOI:10.1007/s13318-018-0501-y.; Chang M., Yu Z., Shenker A., et al. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban. J Clin Pharmacol. 2016;56(5):637-45. DOI:10.1002/jcph.633.; Leil T.A., Frost C., Wang X., et al. Model-based exposure-response analysis of apixaban to quantify bleeding risk in special populations of subjects undergoing orthopedic surgery. CPT Pharmacometrics Syst Pharmacol. 2014;3:e136. DOI:10.1038/psp.2014.34.; Byon W., Sweeney K., Frost C., Boyd R. Population pharmacokinetics, pharmacodynamics, and exploratory exposure-response analyses of apixaban in subjects treated for venous thromboembolism. CPT Pharmacometrics Syst Pharmacol. 2017;6(5):340-9. DOI:10.1002/psp4.12184.; Cirincione B., Kowalski K., Nielsen J., et al. Population pharmacokinetics of apixaban in subjects with non-valvular atrial fibrillation. CPT Pharmacometrics Syst Pharmacol. 2018;7(11):728-38. DOI:10.1002/psp4.12347.; Wang X., Tirucherai G., Marbury T.C., et al. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol. 2016;56(5):628-36. DOI:10.1002/jcph.628.; Zeitouni M., Giczewska A., Lopes R.D., et al. Clinical and pharmacological effects of apixaban dose adjustment in the ARISTOTLE Trial. J Am Coll Cardiol. 2020;75:1145-55. DOI:10.1016/j.jacc.2019.12.060.; Mueck W., Stampfuss J., Kubitza D., Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet. 2014;53:1-16. DOI:10.1007/s40262-013-0100-7; Kubitza D., Becka M., Mueck W., et al. Effect of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct factor Xa inhibitor. Br J Clin Pharmacol. 2010;70(5):703-12. DOI:10.1111/j.1365-2125.2010.03753.x.; Mueck W., Lensing A, Agnelli G., et al. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet. 2011;50(10):675-86. DOI:10.2165/11595320-000000000-00000.; Blech S., Ebner T., Ludwig-Schwellinger E., et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008;36(2):386-99. DOI:10.1124/dmd.107.019083.; Stangier J., Rathgen K., Stahle H., et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64(3):292-303. DOI:10.1111/j.1365-2125.2007.02899.x.; Stangier J., Rathgen K., Stahle H., Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamicsof oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet. 2010;49:259-68. DOI:10.2165/11318170-000000000-00000.; Delanaye P., Guerber F., Scheen A., et al. Discrepancies between the Cockcroft-Gault and Chronic Kidney Disease Epidemiology (CKD-EPI) equations: implications for refining drug dosage adjustment strategies. Clin Pharmacokinet. 2017;56(2):193-205. DOI:10.1007/s40262-016-0434-z.; Earley A., Miskulin D., Lamb E.J., et al. Estimating equations for glomerular filtration rate in the era of creatinine standardization. A systematic review. Ann Intern Med. 2012;156:785-95. DOI:10.7326/0003-4819-156-6-201203200-00391.; Levey A.S., Greene T., Schluchter M.D., et al. Glomerular filtration rate measurement in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group. J Am Soc Nephrol. 1993;4:1159-71.; Levey A.S., Stevens L.A., Schmid C.H., et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604-12. DOI:10.7326/0003-4819-150-9-200905050-00006.; Delanaye P., Mariat C. The applicability of eGFR equations to different populations. Nat Rev Nephrol. 2013;9:513-22. DOI:10.1038/nrneph.2013.143.; Delanaye P., Cavalier E., Mariat C., et al. MDRD or CKD EPI study equations for estimating prevalence of stage 3 CKD in epidemiological studies: which difference? Is this difference relevant? BMC Nephrol. 2010;11:8. DOI:10.1186/1471-2369-11-8. DOI:10.1186/1471-2369-11-8.; Gaspari F., Ruggenenti P., Porrini E., et al. The GFR and GFR decline cannot be accurately estimated in type 2 diabetics. Kidney Int. 2013;84:164-73. DOI:10.1038/ki.2013.47.; MacIsaac R.J., Ekinci E.I., Premaratne E., et al. The chronic kidney Disease-Epidemiology collaboration (CKD-EPI) equation does not improve the underestimation of glomerular filtration rate (GFR) in people with diabetes and preserved renal function. BMC Nephrol. 2015;16:198. DOI:10.1186/s12882-015-0196-0.; Lingli X., Qing Z., Wenfang X. Diagnostic value of the Modification of Diet in Renal Disease and Chronic Kidney Disease Epidemiology Collaboration equations in diabetic patients: a systematic review and meta-analysis. J Int Med Res. 2020;48(6):1-15. DOI:10.1177/0300060520925950.; Matzke G.R., Aronoff G.R., Atkinson A.J., et al. Drug dosing consideration in patients with acute and chronic kidney disease - a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011;80:1122-37. DOI:10.1038/ki.2011.322.; Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1-150. DOI:10.1038/kisup.2012.76; Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41. DOI:10.1159/000180580.; Millar J.A. The Cockroft and Gault formula for estimation of creatinine clearance: a friendly deconstruction. N Z Med J. 2012;125:119-22.; Flamant M., Haymann J.P., Vidal-Petiot E., et al. GFR estimation using the Cockcroft-Gault, MDRD Study, and CKD-EPI equations in the elderly. Am J Kidney Dis. 2012;60:847-9. DOI:10.1053/j.ajkd.2012.08.001.; Maccallum P.K., Mathur R., Hull S., et al. Patient safety and estimation of renal function in patients prescribed new oral anticoagulants for stroke prevention in atrial fibrillation: a cross-sectional study. BMJ Open. 2013;3:e003343. DOI:10.1136/bmjopen-2013-003343.; Hellden A., Odar-Cederlof I., Nilsson G., et al. Renal function estimations and dose recommendations for dabigatran, gabapentin and valaciclovir: a data simulation study focused on the elderly. BMJ Open. 2013;3:e002686. DOI:10.1136/bmjopen-2013-002686.; Melloni C., Peterson E.D., Chen A.Y., et al. Cockcroft-Gault versus modification of diet in renal disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol. 2008;51:991-6. DOI:10.1016/j.jacc.2007.11.045.; Dufour B., Toussaint-Hacquard M., Kearney-Schwartz A. Glomerular filtration rate estimated by Cockcroft-Gault formula better predicts anti-Xa levels than modification of the diet in renal disease equation in older patients with prophylactic enoxaparin. J Nutr Health Aging. 2012;16:647-52. DOI:10.1007/s12603-012-0072-6.; European Medicines Agency. Annex I. Summary of product characteristics: Pradaxa [cited Apr 5, 2020]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf.; European Medicines Agency. Annex I. Summary of product characteristics: Xarelto [cited Apr 5, 2020]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf.; European Medicines Agency. Annex I. Summary of product characteristics: Eliquis [cited Apr 5, 2020]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf.; Andrade J.G., Hawkins N.M., Fordyce C.B., et al. Variability in non-vitamin K antagonist oral anticoagulants dose adjustment in atrial fibrillation patients with renal dysfunction: the influence of renal function estimation formulae. Can J Cardiol. 2018;34(8):1010-8. DOI:10.1016/j.cjca.2018.04.019.; Steinberg B.A., Holmes D.N., Piccini J.P., et al. Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. J Am Heart Assoc. 2013;2:e000535. DOI:10.1161/JAHA.113.000535.; Camm A.J., Amarenco P., Haas S., et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J. 2016;37:1145-53. DOI:10.1093/eurheartj/ehv466.; Yao X., Shah N.D., Sangaralingham L.R., et al. Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. J Am Coll Cardiol. 2017;69:2779-90. DOI:10.21037/atm.2017.09.19.; Steinberg BA, Shrader P, Thomas L., et al. Off-label dosing of non- vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II Registry. J Am Coll Cardiol. 2016;68:2597-604. DOI:10.1016/j.jacc.2016.09.966.; Bell A.D., Gross P., Heffernan M., et al. Appropriate use of antithrombotic medication in Canadian patients with nonvalvular atrial fibrillation. Am J Cardiol. 2016;117:1107-11. DOI:10.1016/j.amjcard.2015.12.055.; Fox K.A., Piccini J.P., Wojdyla D., et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011;32:2387-94. DOI:10.1093/eurheartj/ehr342.; Andreu-Cayuelas J.M., Pastor-Perez F.J., Puche C.M., et al. Impact of variations in kidney function on nonvitamin K oral anticoagulant dosing in patients with atrial fibrillation and recent acute heart failure. Rev Esp Cardiol (Engl Ed). 2016;69:134-40. DOI:10.1016/j.rec.2015.06.021.; Olesen J.B., Lip G.Y., Kamper A.L., et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012;367:625-35. DOI:10.1056/NEJMoa1105594.; Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-51. DOI:10.1056/NEJMoa0905561.; Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in non-valvular atrial fibrillation. N Engl J Med. 2011;365:883-91. DOI:10.1056/NEJMoa1009638.; Sherwood M.W., Nessel C.C., Hellkamp A.S., et al. Gastrointestinal bleeding in patients with atrial fibrillation treated with rivaroxaban or warfarin: ROCKET AF trial. J Am Coll Cardiol. 2015;66:2271- 2281. DOI:10.1016/j.jacc.2015.09.024.; Marijon E., Heuzey J.Y.L., Stuart Connolly S., et al. Causes of death and influencing factors in patients with atrial fibrillation. A competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study. Circulation. 2013;128:2192-201. DOI:10.1161/CIRCULATIONAHA.112.000491.; Hijazi Z., Hohnloser S., Oldgren J., et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation. 2014;129:961-70. DOI:10.1161/CIRCULATIONAHA.113.003628.; Hohnloser S.H., Hijazi Z., Thomas L., et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012;33:2821-30. DOI:10.1093/eurheartj/ehs274.; Eikelboom J., MD, Geno Merli G. Bleeding with direct oral anticoagulants vs warfarin: clinical experience. Am J Emerg Med. 2016;34(11S):3-8. DOI:10.1016/j.ajem.2016.09.046.; Schlieper G., Schwenger V., Remppis A., et al. [Anticoagulation in patients with chronic kidney disease: recommendations from the working group “Heart-Kidney” of the German Cardiac Society and the German Society of Nephrology] Internist (Berl). 2017;58:512-21. DOI:10.1007/s00108-017-0220-5.; Coresh J., Turin T.C., Matsushita K., et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA. 2014;311:2518-31. DOI:10.1001/jama.2014.6634.; Naimark D.M., Grams M.E., Matsushita K., et al. Past decline versus current eGFR and subsequent mortality risk. J Am Soc Nephrol. 2016;27:2456-66. DOI:10.1681/ASN.2015060688.; Chan K.E., Giugliano R.P., Patel M.R., et al. Nonvitamin K anticoagulant agents in patients with advanced chronic kidney disease or on dialysis with AF. J Am Coll Cardiol. 2016;67:2888-99. DOI:10.1016/j.jacc.2016.02.082.; Kooiman J., van der Hulle T., Maas H., et al. Pharmacokinetics and pharmacodynamics of dabigatran 75 mg b.i.d. in patients with severe chronic kidney disease. J Am Coll Cardiol. 2016;67:2442-4. DOI:10.1016/j.jacc.2016.03.516.; Dias C., Moore K.T., Murphy J., et al. Pharmacokinetics, pharmacodynamics, and safety of singledose rivaroxaban in chronic hemodialysis. Am J Nephrol. 2016;43:229-36. DOI:10.1159/000445328.; De Vriese A.S., Caluwe R., Bailleul E., et al. Dose-finding study of rivaroxaban in hemodialysis patients. Am J Kidney Dis. 2015;66:91-8. DOI:10.1053/j.ajkd.2015.01.022.; Steffel J., Verhamme P., Potpara T., et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;00:1-64. DOI:10.1093/eurheartj/ehy136.; Zhu J., Alexander G.C., Nazarian S., Segal J.B. Trends and variation in oral anticoagulant choice in patients with atrial fibrillation. 2010-2017. Pharmacotherapy. 2018;38:907-20. DOI:10.1002/phar.2158.; https://www.rpcardio.com/jour/article/view/2389
-
17
Autoren: et al.
Weitere Verfasser: et al.
Quelle: Rational Pharmacotherapy in Cardiology; Vol 17, No 2 (2021); 206-211 ; Рациональная Фармакотерапия в Кардиологии; Vol 17, No 2 (2021); 206-211 ; 2225-3653 ; 1819-6446
Schlagwörter: atrial fibrillation, apixaban, dabigatran, rivaroxaban, inappropriate dose reduction, фибрилляция предсердий, апиксабан, дабигатран, ривароксабан, необоснованно низкие дозы антикоагулянтов
Dateibeschreibung: application/pdf
Relation: https://www.rpcardio.com/jour/article/view/2429/2139; Timmis A, Townsend N, Gale CP, et al. European Society of Cardiology: Cardiovascular Disease Statistics 2019 (Executive Summary). Eur Heart J Qual Care Clin Outcomes. 2020;6:7-9. DOI:10.1093/ehjqcco/qcz065.; Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developedin collaboration with EACTS. Eur J Cardiothorac Surg. 2016:50(5):e1-e88. DOI:10.1093/ejcts/ezw313.; de Caterina R, Husted S, Wallentin L, et al. Vitamin K antagonists in heart disease: Current status and perspectives (Section III): Position paper of the ESC working group on thrombosis - Task force on anticoagulants in heart disease. Thromb Haemost. 2013;110:1087-107. DOI:10.1160/TH13-06-0443.; Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials. Lancet. 2014;383:955-62. DOI:10.1016/S0140-6736(13)62343-0.; Steinberg BA, Shrader P, Thomas L, et al. Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry. J Am Coll Cardiol. 2016;68:2597-604. DOI:10.1016/j.jacc.2016.09.966.; Mazurek M, Halperin JL, Huisman MV, et al. Antithrombotic treatment for newly diagnosed atrial fibrillation in relation to patient age: the GLORIA-AF registry programme. Europace. 2020;22:47-57. DOI:10.1093/europace/euz278.; Ионин В.А., Барашкова Е.И., Филатова А.Г., и др. Фибрилляция предсердий в когорте амбулаторных пациентов Санкт-Петербурга: встречаемость, факторы риска, антиарит- мическая терапия и профилактика тромбоэмболических осложнений. Артериальная Гипертензия. 2020;26(2):192-201. DOI:10.18705/1607-419X-2020-26-2-192-2018.; Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857-67. DOI:10.7326/0003-4819-146-12-200706190-00007.; Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: An analysis of the RE-LY trial. Lancet. 2010;376:975-83. DOI:10.1016/S0140-6736(10)61194-4.; Wallentin L, Lopes RD, Hanna M, et al. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for Stroke prevention in atrial fibrillation. Circulation. 2013;127:2166-76. DOI:10.1161/CIRCULATIONAHA.112.142158.; Singer DE, Hellkamp AS, Piccini JP, et al. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. J Am Heart Assoc. 2013;2. DOI:10.1161/JAHA.112.000067.; Лукьянов М.М., Марцевич С.Ю., Якушин С.С., и др. Контроль показателя международного нормализованного отношения на фоне терапии варфарином у больных с фибрилляцией предсердий в амбулаторной и госпитальной практике (данные регистров РЕКВАЗА). Рациональная Фарма-котерапия в Кардиологии. 2018;14(1):40-6. DOI:10.20996/1819-6446-2018-14-1-40-46; Connolly SJ, Ezekowitz MD, Yusuf S, et al. Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly identified events in the RE-LY trial. N Engl J Med. 2010;363:1875-6. DOI:10.1056/NEJMc1007378.; Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2009;361:1139-51. DOI:10.1056/NEJMoa0905561.; Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med. 2011;365:883-91. DOI:10.1056/NEJMoa1009638.; Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2011;365:981-92. DOI:10.1056/NEJMoa1107039.; Lip GYH, Clemens A, Noack H, et al. Patient outcomes using the European label for dabigatran: A post-hoc analysis from the RE-LY database. Thromb Haemost. 2014;111:933-42. DOI:10.1160/TH13-09-0734.; Xing LY, Barcella CA, Sindet-Pedersen C, et al. Dose reduction of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: A Danish nationwide cohort study. Thromb Res. 2019;178:101-9. DOI:10.1016/j.thromres.2019.04.007.; Pharithi RB, Ranganathan D, O'Brien J, et al. Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group. Ir J Med Sci. 2019;188:101-8. DOI:10.1007/s11845-018-1837-7.; Steinberg BA, Shrader P, Pieper K, et al. Frequency and outcomes of reduced dose Non-Vitamin K antagonist anticoagulants: Results from ORBIT-AF II (The outcomes registry for better informed treatment of atrial fibrillation II). J Am Heart Assoc. 2018; 7(4):e007633. DOI:10.1161/JAHA.117.007633.; Jacobs MS, van Hulst M, Campmans Z, et al. Inappropriate non-vitamin K antagonist oral anticoagulants prescriptions: be cautious with dose reductions. Neth Heart J. 2019;27:371-7. DOI:10.1007/s12471-019-1267-9.; Ono T, Ikemura N, Kimura T, et al. Contemporary trend of reduced-dose non-vitamin K anticoagulants in Japanese patients with atrial fibrillation: A cross-sectional analysis of a multicenter outpatient registry. J Cardiol. 2019;73:14-21. DOI:10.1016/j.jjcc.2018.09.003.; Cho MS, Yun JE, Park JJ, et al. Pattern and Impact of Off-label Underdosing of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Who are Indicated for Standard Dosing. Am J Cardiol. 2020;125:1332-8. DOI:10.1016/j.amjcard.2020.01.044.; Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330-93. DOI:10.1093/eurheartj/ehy136.; Yao X, Shah ND, Sangaralingham LR, et al. Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction. J Am Coll Cardiol. 2017;69(23):2779-90. DOI:10.1016/j.jacc.2017.03.600.; Kim IS, Kim HJ, Kim TH, et al. Appropriate doses of non-vitamin K antagonist oral anticoagulants in high-risk subgroups with atrial fibrillation: Systematic review and meta-analysis. J Cardiol. 2018;72:284-91. DOI:10.1016/j.jjcc.2018.03.009.; Frost C, Nepal S, Wang J, et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol. 2013;76:776-86. DOI:10.1111/bcp.12106.; Eikelboom JW, Weitz JI. “Real world” use of non-vitamin K antagonist oral anticoagulants (NOACS): Lessons from the dresden NOAC registry. Thromb Haemost. 2015;113:1159-61. DOI:10.1160/TH15- 02-0158.; https://www.rpcardio.com/jour/article/view/2429
-
18
Autoren: et al.
Quelle: Meditsinskiy sovet = Medical Council; № 14 (2021); 68-76 ; Медицинский Совет; № 14 (2021); 68-76 ; 2658-5790 ; 2079-701X
Schlagwörter: дабигатран, non-recommended low doses, atrial fibrillation, apixaban, rivaroxaban, dabigatran, нерекомендуемые сниженные дозы, фибрилляция предсердий, апиксабан, ривароксабан
Dateibeschreibung: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/6428/5824; Bassand J.P., Apenteng P.N., Atar D., Camm A.J., Cools F., Corbalan R. et al. GARFIELD-AF: a worldwide prospective registry of patients with atrial fibrillation at risk of stroke. Future Cardiol. 2021;17(1):19–38. https://doi.org/10.2217/fca-2020-0014.; Boriani G., Pettorelli D. Atrial fibrillation burden and atrial fibrillation type: Clinical significance and impact on the risk of stroke and decision making for long-term anticoagulation. Vascul Pharmacol. 2016;83:26–35. https://doi.org/10.1016/j.vph.2016.03.006.; Odutayo A., Wong C.X., Hsiao A.J., Hopewell S., Altman D.G., Emdin C.A. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. BMJ. 2016;354:i4482. https://doi.org/10.1136/bmj.i4482.; Pistoia F., Sacco S., Tiseo C., Degan D., Ornello R., Carolei A. The Epidemiology of Atrial Fibrillation and Stroke. Cardiol Clin. 2016;34(2):255–268. https://doi.org/10.1016/j.ccl.2015.12.002.; Rizos T., Wagner A., Jenetzky E., Ringleb P.A., Becker R., Hacke W., Veltkamp R. Paroxysmal atrial fibrillation is more prevalent than persistent atrial fibrillation in acute stroke and transient ischemic attack patients. Cerebrovasc Dis. 2011;32(3):276–282. https://doi.org/10.1159/000330348.; Steinberg B.A., Kim S., Fonarow G.C., Thomas L., Ansell J., Kowey P.R. et al. Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Am Heart J. 2014;167(5):735–742.e2. https://doi.org/10.1016/j.ahj.2014.02.003.; Pattullo C.S., Barras M., Tai B., McKean M., Donovan P. New oral anticoagulants: appropriateness of prescribing in real-world setting. Intern Med J. 2016;46(7):812–818. https://doi.org/10.1111/imj.13118.; Pharithi R.B., Ranganathan D., O’Brien J., Egom E.E., Burke C., Ryan D. et al. Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group. Ir J Med Sci. 2019;188(1):101–108. https://doi.org/10.1007/s11845-018-1837-7.; Armbruster A.L., Buehler K.S., Min S.H., Riley M., Daly M.W. Evaluation of dabigatran for appropriateness of use and bleeding events in a community hospital setting. Am Health Drug Benefits. 2014;7(7):376–384. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4268768.; Moudallel S., Steurbaut S., Cornu P., Dupont A. Appropriateness of DOAC Prescribing Before and During Hospital Admission and Analysis of Determinants for Inappropriate Prescribing. Front Pharmacol. 2018;9:1220. https://doi.org/10.3389/fphar.2018.01220.; Belen E., Canbolat I.P., Bayyigit A., Helvaci A., Pusuroglu H., Kilickesmez K. A new gap in the novel anticoagulants’ era: undertreatment. Blood Coagul Fibrinolysis. 2015;26(7):793—797. https://doi.org/10.1097/MBC.0000000000000349.; Rubboli A. Low or reduced? Semantics of the doses of new oral anticoagulants. G Ital Cardiol (Rome). 2017; 18(9 Suppl. 2):3S–9S. https://doi.org/10.1714/2795.28297.; Connolly S.J., Ezekowitz M.D., Yusuf S., Eikelboom J., Oldgren J., Parekh A. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139—1151. https://doi.org/10.1056/NEJMoa0905561.; Shen N.N., Zhang C., Hang Y., Li Z., Kong L.C., Wang N. et al. Real-World Prevalence of Direct Oral Anticoagulant Off-Label Doses in Atrial Fibrillation: An Epidemiological Meta-Analysis. Front Pharmacol. 2021;12:581293. https://doi.org/10.3389/fphar.2021.581293.; Hindricks G., Potpara T., Dagres N., Arbelo E., Bax J.J., Blomström-Lundqvist C. et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373–498. https://doi.org/10.1093/eurheartj/ehaa612.; Andrade J.G., Aguilar M., Atzema C., Bell A., Cairns J.A., Cheung C.C. et al. Members of the Secondary Panel. The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation. Can J Cardiol. 2020;36(12):1847–1948. https://doi.org/10.1016/j.cjca.2020.09.001.; Joung B., Lee J.M., Lee K.H., Kim T.H., Choi E.K., Lim W.H. et al.; KHRS Atrial Fibrillation Guideline Working Group. 2018 Korean Guideline of Atrial Fibrillation Management. Korean Circ J. 2018;48(12):1033–1080. https://doi.org/10.4070/kcj.2018.0339.; JCS Joint Working Group. Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2013). Circ J. 2014;78(8):1997–2021. https://doi.org/10.1253/circj.cj-66-0092.; Li R.J., Caughey G.E., Shakib S. Appropriateness of inpatient dosing of direct oral anticoagulants for atrial fibrillation. J Thromb Thrombolysis. 2021. https://doi.org/10.1007/s11239-021-02528-x.; Granger C.B., Alexander J.H., McMurray J.J., Lopes R.D., Hylek E.M., Hanna M. et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992. https://doi.org/10.1056/NEJMoa1107039.; Frost C., Nepal S., Wang J., Schuster A., Byon W., Boyd R.A. et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol. 2013;76(5):776–786. https://doi.org/10.1111/bcp.12106.; Zeitouni M., Giczewska A., Lopes R.D., Wojdyla D.M., Christersson C., Siegbahn A. et al. Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial. J Am Coll Cardiol. 2020;75(10):1145–1155. https://doi.org/10.1016/j.jacc.2019.12.060.; Gulilat M., Tang A., Gryn S.E., Leong-Sit P., Skanes A.C., Alfonsi J.E. et al. Interpatient Variation in Rivaroxaban and Apixaban Plasma Concentrations in Routine Care. Can J Cardiol. 2017;33(8):1036–1043. https://doi.org/10.1016/j.cjca.2017.04.008.; Salmasi S., Loewen P.S., Tandun R., Andrade J.G., De Vera M.A. Adherence to oral anticoagulants among patients with atrial fibrillation: a systematic review and meta-analysis of observational studies. BMJ Open. 2020;10(4):e034778. https://doi.org/10.1136/bmjopen-2019-034778.; Camm A.J., Cools F., Virdone S., Bassand J.P., Fitzmaurice D.A., Arthur Fox K.A. et al. Mortality in Patients With Atrial Fibrillation Receiving Nonrecommended Doses of Direct Oral Anticoagulants. J Am Coll Cardiol. 2020;76(12):1425–1436. https://doi.org/10.1016/j.jacc.2020.07.045.; Ashraf H., Agasthi P., Shanbhag A., Mehta R.A., Rattanawong P., Allam M. et al. Long-Term Clinical Outcomes of Underdosed Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Atrial Flutter. Am J Med. 2021;134(6):788–796. https://doi.org/10.1016/j.amjmed.2020.12.022.; Yao X., Shah N.D., Sangaralingham L.R., Gersh B.J., Noseworthy P.A. NonVitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction. J Am Coll Cardiol. 2017;69(23):2779–2790. https://doi.org/10.1016/j.jacc.2017.03.600.; de Almeida J.P.H.C.L., Martinho A.S., Girão A., Barreiro I., Milner J., Ferreira M.J.V. et al. Novel anticoagulants in an older and frail population with atrial fibrillation: the effect of inappropriate dosing on clinical outcomes. Eur Geriatr Med. 2020;11(5):813–820. https://doi.org/10.1007/s41999-020-00343-w.; Cho M.S., Yun J.E., Park J.J., Kim Y.J., Lee J., Kim H. et al. Pattern and Impact of Off-label Underdosing of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Who are Indicated for Standard Dosing. Am J Cardiol. 2020;125(9):1332–1338. https://doi.org/10.1016/j.amjcard.2020.01.044.; Suzuki S., Yamashita T., Akao M., Okumura K. Clinical implications of assessment of apixaban levels in elderly atrial fibrillation patients: J-ELD AF registry sub-cohort analysis. Eur J Clin Pharmacol. 2020;76(8):1111–1124. https://doi.org/10.1007/s00228-020-02896-y.; Proietti M., Romanazzi I., Romiti G.F., Farcomeni A., Lip G.Y.H. Real-World Use of Apixaban for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis. Stroke. 2018;49(1):98–106. https://doi.org/10.1161/STROKEAHA.117.018395.; Escobar C., Martí-Almor J., Pérez Cabeza A., Martínez-Zapata M.J. Direct; Oral Anticoagulants Versus Vitamin K Antagonists in Real-life Patients With Atrial Fibrillation. A Systematic Review and Meta-analysis. Rev Esp Cardiol (Engl Ed). 2019;72(4):305–316. https://doi.org/10.1016/j.rec.2018.03.009.; Lip G.Y.H., Keshishian A.V., Zhang Y., Kang A., Dhamane A.D., Luo X. et al. Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With High Risk of Gastrointestinal Bleeding. JAMA Netw Open. 2021;4(8):e2120064. https://doi.org/10.1001/jamanetworkopen.2021.20064.
-
19
Autoren: et al.
Quelle: Медицина в Кузбассе, Vol 18, Iss 3, Pp 36-40 (2019)
Schlagwörter: фибрилляция предсердий, дабигатран, апискабан, ривароксабан, варфарин, ишемический инсульт, кровотечения, Medicine
Dateibeschreibung: electronic resource
-
20
Autoren: et al.
Quelle: Безопасность и риск фармакотерапии, Vol 0, Iss 2, Pp 28-32 (2018)
Schlagwörter: риск развития кровотечений, дабигатран, антидот, идаруцизумаб, the risk of bleeding, dabigatran, antidote, idarutsizumab, Therapeutics. Pharmacology, RM1-950
Dateibeschreibung: electronic resource
Nájsť tento článok vo Web of Science